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Title: Operating profitability in branded pharmaceutical firms 
Abstract 
This work project focuses in operating profitability of branded pharmaceuticals, measured by 
return on assets (ROA). It gives insights about key ROA drivers, by breaking down this ratio 
into gross sales margin, assets turnover and operating risk. Data from consolidated financial 
statements of 26 US- and European-based firms for the period 2007-2011 is used in univariate 
and bivariate analyses. Results suggested that firm size and country-membership do not 
significantly correlate with ROA. However, differences between branded pharmaceuticals’ 
regions are explored and significant correlations are found between operating profitability and 
strategic choices variables, namely product portfolio diversification, growth choices and 
investment.  
Key words: Operating profitability, Ratio analysis, Branded pharmaceuticals, US and Europe 
1. Introduction 
The pharmaceutical industry is one of the most inventive, innovative and lucrative of the 
so-called “high-tech” industries (Kesic, 2008). Healthcare expenditure is more significant in 
developed countries, namely in the US and in European countries
1
, where most Big and Mid 
Pharma players are based
2
. However, worldwide pharmaceutical sales’ growth rate has been 
dropping steadily from around 9% in 2003 to 7.1% in 2007 and to 5.1% in 2011
3
. Moreover, 
while the compound annual growth rate (CAGR) in the period 2007-2011 for established 
markets’ prescription sales presented one-digit growth rates (Europe with 4.9% and North 
America with 3.5%), emerging markets presented double-digit growth rates (Asia, Africa and 
Australia with 15.5% and Latin America with 12.3%). Apart from underlining the developed 
                                                          
1
 Europe and North America account for 65% of the prescription sales’ market worldwide in 2011 (US is 
the largest market – 38%), according to the IMS Healthcare Market Prognosis, released on May, 2012. 
2
 According to Datamonitor Healthcare (database accessed on March, 23
rd
 of 2013), Big Pharma entails 
the world’s top branded pharmaceuticals (revenue above ten billion USD) and Mid Pharma entails the 
following most important players (revenue between five and ten billion USD), excluding Japanese. 
3
 Growth rates available on the IMS Healthcare Market Prognosis Report 2012. Appendix 9.1 provides 
the evolution of worldwide pharmaceutical market growth rates in the period between 2003 and 2011. 
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countries’ declining scenario, these values highlight the depolarization process that is taking 
place in the pharmaceutical industry, regarding sales’ region division.  
Business-specific factors also hold down profitability of branded pharmaceuticals – they 
sell branded small molecules, biologics, vaccines and emerging therapies
4
. Research and 
development (R&D) productivity is declining, partly as result of legislation and regulation 
changes, influencing profitability, as branded pharmaceuticals heavily rely on this type of 
investment. Additionally, brands’ flagship products are approaching patent expiry, facing 
potential competition from generics. Both declining R&D productivity and the patent cliff 
affect fundamental points of differentiation of branded pharmaceuticals. These factors cement 
competition from generic manufacturers and high-growth firms based in emerging markets - 
benefiting from those countries’ improved economical situation. Hence, there has been 
occurring a decline in operating profitability of branded pharmaceuticals over last years. 
Considering the top ten prescription sales branded pharmaceuticals, figure 1 shows that 
while average return on equity increases between 2007 and 2011, average return on assets 
(ROA) slightly decreases in the same period. Hence, branded pharmaceuticals’ operating 
profitability is holding back overall profitability growth and so it becomes paramount to get 
insights regarding factors behind such decline. Additionally, to the best of our knowledge, 
there is no evidence probing which factors influence operating profitability - country-, 
industry- or firm-specific characteristics: namely operating risk, sales margin or turnover.  
 
Figure 1: Profitability for the top ten branded pharmaceuticals (source: Datamonitor Healthcare) 
                                                          
4
 Appendices 9.2.a and 9.2.b provide a segmentation of the healthcare industry. 
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Thus, it is of the utmost importance to understand key operating profitability drivers in 
this industry. Accordingly, the research drafts operating patterns in the pharmaceutical 
industry in order to identify correlations between profitability and strategic choices, namely 
R&D investment, portfolio diversification and sales’ growth originated by external sources. 
Additionally, this research aims to test country and size correlation with profitability, and to 
understand differences between US and European firms. The DuPont Model is used in order 
to breakdown ROA, and in order to provide insights regarding each company’s investment 
decisions. This characterization of branded pharmaceuticals based in developed countries is 
performed using a sample of 26 European and US branded pharmaceutical firms. 
This work project proceeds as follows. Section two presents key concepts and the 
framework for analysis. Section three reviews the literature entailing financial ratios’ and 
pharmaceuticals’ analyses. Section four highlights branded pharmaceuticals differentiating 
characteristics concerning operating profitability. Section five describes the methodology: 
research questions, sample selection criteria, the definition of operationalized variables and 
data. Section six exposes the results and in section seven final conclusions are drawn. 
2. Analysis framework: Return on assets and its breakdown 
Profitability ratios are financial statement analysis’ (FSA) tools used to measure the 
management’s effectiveness on generating returns on invested capital. Amongst the mostly 
used ratios is ROA which emphasizes the return on management’s investing decisions
5
. There 
are several ways of calculating this ratio, but the mostly used by FSA is the following: 
       
     
             
     
       
     
            
       
 
            
      
     
 
      
       
    
      
                                                          
5
 Although taxation and financial leverage compound are important to understand firms’ profitability (through the 
study of ROE, which entails both these compounds and ROA), this research focuses in the investing decisions. 
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In order to understand which factors influence ROA, this ratio can be broken down through 
the DuPont model
6
. In this research three different ratios are used: risk - operating leverage 
(1/DOL), margin - gross sales margin (GSM), and rotation - asset turnover (AT).     
The degree of operating leverage (DOL) measures firm’s operating risk - how much 
(percent) operating results change if sales change (one percent), i.e. firms with larger 1/DOL 
have smaller proportions of fixed costs, presenting higher levels of profitability (ceteris 
paribus). This enables firms to present lower break-even points (BEP)
7
 and larger margins of 
safety in percent of sales (MS)
8
 – values highlighting lower operating risk profiles. Hence, 
1/DOL reflects management’s ability in handling firm size or, for instance, choosing 
outsourced versus in-housed functions or the mix between labor and capital investment. 
Gross sales margin (GSM) represents the amount of sales retained by the firm after 
deducting all variable costs associated with the goods sold and services rendered. Higher 
levels of GSM lead to higher levels of profitability (ceteris paribus). For instance, as result of 
their bargaining power with customers or suppliers, firms are able to charge higher prices 
when selling; or to incur in lower costs when purchasing. A higher GSM is also influenced by 
production efficiency – the use of fewer raw materials for the same amount of sold goods. 
Asset turnover (AT) shows how efficient a firm is in generating sales through its set of 
total assets, i.e. the amount of sales generated by each monetary unit of investment 
(represented by total assets). Firms presenting higher levels of AT show higher profitability 
levels (ceteris paribus). Other activity ratios, which evaluate relationships between output 
generated and the assets needed to sustain such activities (White et. al, 1998), complement 
the AT ratio analysis: fixed assets turnover (FAT)
9
, inventory turnover (IT)
10
, days to sell 
                                                          
6
 This model usually breaks down ROA in two ratios: operating profit margin (OPM) and asset turnover (AT). 
7
 BEP is the minimum sales level through which firms cover all their fixed operating costs. 
8
 MS indicates how far from BEP a firm is operating or how much are actual sales higher than the BEP. 
9
 FAT - Sales over total fixed assets - it represents the productivity of the firm’s tangible fixed assets.  
10
 IT - Calculated by dividing cost of goods sold by average inventory and it represents stocks’ rotation.  
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inventory (DTSI)
11
, average collection period (ACP)
12
 and average payment period (APP)
13
. 
Although 1/DOL, GSM and AT are positively correlated with ROA, firms’ strategies and the 
industries in which they are playing highly affect the value of each of these three ratios. Often, 
decisions that lead to an increase in one of the mentioned ratios lead to a decrease in one of 
the other two. An example is a merger with a supplier or a customer – this type of merger 
normally increases the operating profit margin (OPM)
14
, but this increase is offset by a 
reduction in assets turnover (Brealey, Myers & Allen, 2011).  
Profitability analysis through the study of financial ratios (entailing ROA and other) is 
widely used by authors considering different industries and variables or hypotheses. This 
framework is applied to the branded pharmaceuticals with the aim of studying operating 
profitability drivers: correlation between strategic choices and ROA, country or size and ROA 
and differences among branded pharmaceutical firms based in developed countries.  
3. Literature Review  
Previous research
15
 related to ratio analyses includes, among others: DuPont model 
related research (Parés, 1980; and Soliman, 2008); Firm- or country-focused ratio analyses 
(Serrano, Molinero and Gallizo, 2001; Collier et. al, 2004; Marques, 2011); Pharmaceutical 
industry ratio analyses (Hossan & Habib, 2010; Tavakolli et. al, 2010; Serrano & Mavarez, 
2011; Majumder & Rahman, 2011); and strategic issues (Guo & Cao, 2012; Porter, 1987).  
DuPont model breaks profitability ratios in several components which have explanatory 
power with respect to changes in profitability (Soliman, 2008). Parés (1980) develops the 
ROED
16
 - the author highlights the pitfalls regarding the use of financial ratios and proposes 
an empirical model to measure firm’s financial leverage effects on corporate profitability. All 
                                                          
11
 Represents how many days a firm takes, on average, to sell its finished goods. 
12
 Months a firm takes, on average, to collect money from sales (turning accounts receivable into cash). 
13
 Months a firm takes, on average, to pay to its suppliers. 
14
 Operating profit margin is a compound ratio, resulting from multiplication of GSM by 1/DOL. 
15
 Appendix 9.3 provides a summary of all studied research.  
16
 ROED – return on equity decomposition model, which is a variation of the DuPont Model. 
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ratios presented represent virtual situations to demonstrate validity of the hypotheses 
formulated. Describing the importance of DuPont model, Soliman (2008) highlights the 
breakdown of ROA into two multiplicative factors, namely: operating profit margin (OPM) 
and asset turnover (AT)
17
. The author tests whether both constructs hold a correlation with 
stock market returns and he concludes that DuPont components are a valid information source 
about a firm’s operating characteristics and, consequently, about a firm’s future earnings.  
Other studies adopt a practical approach, focusing either in specific industries, particular 
countries or firm ratio analyses. Using the BACH
18
 database, Serrano, Molinero & Gallizo 
(2001) study country- and size-effects of financial ratios, performing multivariate statistical 
techniques in a sample comprised by three size groups, eleven European countries and fifteen 
financial ratios for a fourteen-year period. It is found that financial ratios reflect the size of a 
firm (measured by turnover). However, differences in size are not reflected in levels of 
profitability, they only affect the way through which profitability is obtained. In order to test 
country-effects, they perform a cluster analysis, identifying three strategic groups – Latin, 
Scandinavian and German. The authors conclude that profitability is not affected by size and 
that differences arise when country-features are compared. Collier et. al (2004) build a ratio 
analysis for MOTOROLA, considering that the firm operates in different business segments. The 
authors demonstrate how to compute ratios, emphasizing the difficulties of heterogeneous 
data sets. They also perform a DuPont analysis using 1999-2002 MOTOROLA financial 
statement figures and comparing the results to industry averages. Their research concludes 
that financial ratio analysis becomes difficult when companies do not fall into a single 
industry (Collier et. al, 2004) and that conclusions might be diverse if different industries are 
considered as benchmark. Recently and also based in the DuPont model, Marques (2011) 
                                                          
17
 Also discovering that there is a significant negative correlation between both constructs. 
18
 BACH (Bank for the Accounts of Companies Harmonised) is a database set up in the eighties of the 
past century at the initiative of central banks of some European countries. It contains aggregated and 
harmonized information about the financial statements of non-financial companies from eleven European 
countries, the US, and Japan.  
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compares ROE of Portuguese and Brazilian listed companies from selected industries for the 
period 2005-2010. He aims to analyze differences in ratios as a result of country- or industry-
specific characteristics. Marques (2011) concludes that, while Portuguese firms benefit more 
from tax burden and financing decisions - lower corporate taxes and interest rates - Brazilian 
firms benefit more from their investing decisions. Marques’ research focuses the analysis in 
tax burden and financing decisions, leaving investing decisions for future research.  
While some researchers focus in more than one industry, others study a single industry. 
Hossan & Habib (2010) analyze two pharmaceutical firms in Bangladesh: data from the 2007 
and 2008 annual reports of BEXIMCO and SQUARE companies is the input in order to compute 
several financial ratios and analyze liquidity, profitability, financial structure and market value 
of both companies as well as identifying important differences between them. Tavakolli et. al 
(2010) use a fuzzy logic method which helps investors evaluate firms’ performance through 
ranking of firms included in each industry. In this specific case, the authors rank firms in the 
Iranian pharmaceutical industry according to several ratios, using data from nineteen firms 
listed in the Tehran Stock Exchange in 2007. This study shows the importance of considering 
overall industry information when performing firms’ performance analysis
19
. Serrano & 
Mavarez (2011) perform a strategic group analysis in the Spanish pharmaceutical industry. 
The authors use seven variables which reflect firms’ strategic choices: internationalization, 
diversification, R&D efficiency, R&D strategy, size and scale economies; and three variables 
as performance indicators: ROE, ROA and OPM. Ratios for the period 2000-2003 are 
computed for a sample of 45 medium and large pharmaceutical laboratories with 
manufacturing capabilities in Spanish soil. A cluster analysis groups those companies into 
three major sets: national capital, foreign capital and mixed capital. It is confirmed that there 
are differences among strategic groups regarding some indicators: “Spanish multinationals” 
                                                          
19
 Financial ratios should not be analyzed in absolute terms, but rather compared to industry averages. 
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perform better and have a higher level of diversification (measured as the number of therapy 
areas). However, the authors conclude that the adoption of different strategies does not 
explain the differences in firms’ profitability levels, as they do not find significant correlations 
between the set of each group’s strategic choices and its firms’ profitability level. Majumder 
& Rahman (2011) perform a market description of the Bangladeshi pharmaceutical market, 
measuring nine firms’ performance through a big array of ratios for the period between 2005 
and 2008. The authors conclude that profitability, liquidity and solvency levels of most of the 
analyzed companies have been deteriorating over time and some of them are near bankruptcy.  
There is a raising concern about the effects of strategic choices in profitability, and that is 
one of the main factors in this research. For example, Guo & Cao (2012) conclude that there 
is not a consensually accepted relationship between the degree of diversification
20
 and firm 
performance
21
. The authors re-examine this relationship by studying a sample of firms with 
different diversification levels: consisting in all firms with available data on the Compustat 
industry segment database between 1996 and 2002. They conclude that there is a significant 
positive relationship between firm performance and diversification. However, benefits of 
diversification get smaller if firms engage in more than three different sectors. Regarding this 
issue, Porter (1987) stated that there is no universal recipe, but the best portfolio management 
is generally associated with a certain limitation to the type of businesses in which a firm acts.  
The only research approaching the relationship between strategic choices and 
profitability in the pharmaceutical industry is the one performed by Serrano & Mavarez 
(2011) regarding the Spanish market. Research in the pharmaceutical industry focuses, to the 
best of our knowledge, in pure description of national markets, never analyzing possible 
correlations
22
. When considering ratio analyses entailing many industries, the research focus 
seems to be turned to financing decisions’ repercussions on profitability. Therefore, this 
                                                          
20
 Measured through the number of sectors in which firms play. 
21
 Measured through Tobin’s q, which is designed to measure present value of future cash flows.  
22
 As it is observed in Majumder & Rahman (2011), Hossan & Habib (2010) and Tavakolli et. al (2010). 
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research fills a gap in the previous literature, since it examines the worldwide branded 
pharmaceutical industry. Also, it shifts the focus to investing decisions, examining possible 
correlations between strategic choices and profitability, and it breaks down ROA in three 
ratios instead of two ratios observed in previous literature. Additionally, it tests country- and 
size-correlation with profitability and explores differences between US and European firms.  
4. Pharmaceutical Industry Summarized Profile 
Since this research focuses in the operating profitability of branded pharmaceuticals, it is 
imperative to highlight differentiating characteristics these firms present
23;24
 - Figure 2 
highlights the most important factors shaping this industry. Firstly, it presents a very 
conservative approach to financing – low debt-to-equity.  As previously mentioned, the 
industry is highly lucrative, and firms present high GSM through patented products’ sales. 
They also leverage their brand equity and expertise in the marketplace in order to sustain 
competitive advantage. However, this industry presents a low AT, as it involves risky 
investments. In parallel, fixed costs (FC) are high – being R&D the most relevant. R&D 
investment is crucial to the sustainability of branded pharmaceuticals as these efforts allow 
firms to discover new medical compounds – however, only about one in ten thousand 
discovered chemical compounds prove to be medically effective and safe to become approved 
medicines (Davidson & Greblov, 2008). Consequently, R&D efficiency is imperial to 
determine firms’ success in the market. Nevertheless, firms face decreasing R&D efficiency, 
i.e. they spend more of their resources to obtain fewer outcomes than before. In addition, 
marketing & sales expenditure levels are extremely relevant to increase brand loyalty and 
customer retention - even more critical when drugs are near patent expiry, as firms need to 
maintain competitive advantage over generic manufacturers in order to charge premium 
                                                          
23
 Appendix 9.4 provides comparative ratio averages analysis for four different industries (ratios collected 
from the website www.reuters.com, accessed on March, 23
rd
 of 2013). 
24
 Appendix 9.5 provides a detailed SWOT analysis of the Developed countries’ branded pharmaceutical 
industry, complementing figure two, present in this section. 
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prices. It becomes clear why successful pharmaceuticals invest more than 25 per cent of their 
revenues in marketing and sales initiatives (Kesic, 2008). Firms are restructuring their value 
chain in order to enhance R&D operations as well as their marketing initiatives’ efficiency.  
 
Figure 2: SWOT analysis of the branded pharmaceutical firms in developed countries 
As identified in figure 2, one of the biggest threats in this market is the expansion of 
generics. Generic firms market original products’ equivalents and price them much lower 
(Kesic, 2008). Difficult-to-make generics market is one of the most attractive segments of the 
Pharmaceutical industry
25
. Generics’ sales are expected to grow worldwide as a result of the 
patent cliff - by 2016, patented pharmaceuticals with global annual sales totaling 200 billion 
USD are expected to lose patent protection and face potential competition from generics
26
. 
Besides, there has been an increasing regulatory oversight in diverse areas ranging from 
manufacturing practices to legislative involvement in pricing and cost containment (PwC, 
2008)
27
. Hence, governmental healthcare providers’ pricing pressures highly contribute to the 
detriment of branded pharmaceuticals’ profitability and to the generics’ market growth. 
However, some important opportunities arise in this industry. The competitive landscape is 
not local anymore. “Blockbuster” products are sold on a global rather than regional basis
28
. 
This trend enables companies to achieve scale economies and to benefit from internationally 
                                                          
25
 Novartis 2011 Annual Report. 
26
 Evaluate Pharma’s website accessed on March, 15
th
 of 2013. 
27
 PwC (2008): Key accounting, auditing and financial reporting risks in the pharmaceutical industry. 
28
 Factiva - Online Database consulted on March, 10
th
 of 2013.
 
 
 
Strengths: 
 
     - High gross sales margin; 
     - Solid position and knowledge of the market; 
     - Internationally integrated value chains; 
     - Brand-equity. 
 
Weakness: 
 
     - Low assets turnover; 
     - High reliance on R&D and Marketing & Sales; 
     - Government as the major customer. 
 
  
Opportunities: 
 
     - Growth of alternative markets; 
     - Market consolidation and globalization; 
     - Population ageing;  
     - Increasing life expectancy; 
 
 
Threats: 
 
     - Declining R&D efficiency  
     - Rising pressure on pricing; 
     - Patent cliff and generics market expansion; 
     - Regulatory pressures. 
 
SWOT  
(Developed countries' 
branded pharmaceuticals) 
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integrated value chains, what intensifies the industry’s globalization process. Also, there is a 
fast paced consolidation of the industry – firms join efforts to complement each other and 
achieve strategic advantages
29
. Also, instead of developing a product from scratch, firms are 
increasingly shopping for mid-to-late-stage pipeline candidates
30
. It is important to underline 
that pharmaceutical portfolio management is one of the most important determinants of long-
term prosperity of research-oriented pharmaceutical firms (Davidson & Greblov, 2008). New 
geographic markets, business segments or therapy areas are important opportunities that many 
leading players are investing on in order to to enhance profitability.  
Additionally, the branded pharmaceuticals industry in developed countries is very 
competitive, presenting a low level of new entrants’ threat due to its high entry costs (R&D) 
and regulatory constraints. Moreover, there is a high level of threat of substitution due to the 
“parallel” generics’ market growth. While supplier bargaining power is low, buyer bargaining 
power is medium-to-high, as the major customers are governmental firms
31
.  
5. Methodology 
This research aims at giving insight about operating profitability drivers in the branded 
pharmaceutical industry, exploring profitability differences for US and European firms, 
country- and size-correlation with operating profitability and, correlations between 
profitability and strategic choices (three variables are created denoting vital strategic issues).  
5.1 Variables definition 
“ROA components” entail the three ratios resulting from ROA breakdown – GSM, 
1/DOL and AT
32
. The variable “country” represents each firm headquarters’ country and the 
variable “region” represents the region the HQs are in - split in two possibilities: US and 
Europe. The variable “size” is represented by each firm’s total assets value in US dollars.  
                                                          
29
 Through joint-ventures, strategic alliances, co-development, M&A or a combination of the four types. 
30
 IMAP Healthcare Report 2011. 
31
 Appendix 9.6 provides a Porter’s Five Forces Analysis of the global branded pharmaceuticals market. 
32
 Described in section two – Framework for analysis. 
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As pharmaceutical firms are highly investing in new therapy areas, it is vital to create a 
measure of portfolio diversification. In order to do that, it is developed the Concentration 
ratio (CR) which is similar to a Herfindahl Index (HHI). The variable is defined as follows:  
                            
   
            
       
with     standing for firm’s worldwide sales in therapy area i in the year t. This index is 
similar to a HHI like the one used by Doaei et. al (2012). Hence, higher CR levels represent 
lower diversification - firm’s sales reliance on fewer therapy areas; i.e. the higher the ratio, the 
more concentrated firm sales are in fewer therapy areas. This ratio considers the effect of the 
number of therapy areas and the importance of each therapy area in the total amount of sales. 
Another important issue is the industry’s increasing consolidation. A ratio is created in 
order to analyze firms’ growth choices: External growth source (EGS). The equation is: 
                                     
                         
            
     
Externally sourced sales are generated through sources totally or partially outside the 
company, comprising products resulting from M&A, co-development or strategic 
partnerships (as opposed to in-house developed products’ sales). Higher EGS ratios levels 
represent higher sales’ level coming from totally or partially external sources. 
One of the most important issues in the pharmaceutical industry is R&D investment. 
R&D over sales represents the amount of generated year sales that are channeled back to 
investment in the R&D function in order to discover new drugs. The calculation is as follows: 
                           
                
            
     
5.2 Research Questions (RQ)   
The aforementioned variables are used to answer the RQ listed below. The analyzed RQ 
are split in three parts. The first part comprises an univariate analysis in order to study firms’ 
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operating characteristics. The second part entails a non-hierarchical clustering
33
 and 
correlation coefficient
34
 analyses. The third part studies correlations between strategic choices 
and profitability using correlation coefficients. The basic RQ of the first part is the following: 
RQ.1 – Do ROA components significantly diverge between European and US firms? 
After characterizing European and US investing decisions, the sample is used altogether in 
order to test country- and size-correlation with ROA. The RQ are the following two: 
RQ.2 – Is the country and region where a firm is based related to ROA?  
RQ.3 – Is firm size related to ROA? 
At last, correlation between strategic choices and ROA is tested. The corresponding RQ are:  
RQ.4 - Is the concentration ratio (CR) related to ROA? 
RQ.5 - Is the external growth source ratio (EGS) related to ROA? 
RQ.6 - Is the level of R&D/sales related to ROA? 
Correlations are considered significant at a 95% confidence level (correlations done in SPSS). 
5.3 Data Source and Sample Selection 
In order to answer the aforementioned RQ, all financial data is withdrawn from 
Datamonitor Healthcare (DH)
35
. There is a matching process
36
 between this secondary data 
and firms’ consolidated annual reports in order to ensure its validity - when disparities appear, 
figures from DH are assumed in order to maintain the same information source. The sample 
selection method was a non-probabilistic purposive method - a judgment sampling
37
. This 
involves the choice of sample units which are in the best position to provide the information 
                                                          
33
 A non-hierarchical clustering is a procedure that first assigns or determines a cluster centre and then 
groups all objects within a pre-specified threshold value from the centre (Malhotra & Birks, 2006). 
34
 The correlation coefficient between two variables x and y is defined as      
        
    
, where cov 
stands for the covariation between the two variables and σ stands for the standard deviation. 
35
 Database centered in the pharmaceutical industry. 
36
 A sample of figures from DH is matched with firms’ annual reports – all differences are immaterial. 
For example: BRISTOL-MYERS SQUIBB’s 2011 inventory value is 1,384m USD according to both the firm’s 
annual report and the used database. MERCK KGAA’s 2010 R&D value is 1,397m EUR according to the 
firm’s annual report. When converted into USD at the 2010 average exchange rate – using 31-12-09 rate: 
1.4406 and 31-12-10 rate: 1.3362 - the value is 1,940m EUR, while the database value is 1,944m EUR. 
37
 See appendix 9.7 for the sample selection criteria. 
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required (Sekaran, 2000). The research population is branded pharmaceuticals based in 
developed countries. The first criterion is to select firms based either in European countries or 
in the US – target regions. The second criterion is to select the top twenty prescription sales’ 
firms from each region. However, as some of them present heterogeneous information
38
 or 
hold great sales amount on generics, the third criterion leads to choose only thirteen branded 
pharmaceutical firms from each region – in the US, only thirteen of those firms disclose all 
required information. In Europe, thirteen firms are selected in order to maintain an equal 
number among regions - the selected countries are: Denmark, Germany, France, Switzerland, 
Belgium, Ireland and the UK, as they present the highest number of Big and Mid Pharma 
firms. Then, firms with higher prescription sales are selected. Data from financial statements, 
representing annual worldwide accounts, is used for this research, and covers the period 2007-
2011 for the 26 firms
39
. This period fits the purpose of this research: as the pharmaceutical 
industry is denoting a fast-paced change, it would not be valuable to compare financial ratios 
before 2007. Besides, 2011 is the most recent period with available information. 
This sample of 26 firms
40
 includes all top12 prescription sales’ firms in 2011
41
 - 
combining sales of around 55 percent of total market
42
. Although sales are an important 
criterion, this sample presents great diversity
43
 regarding size, age and product portfolio: 
annual sales’ levels range between one and almost 70 billion USD, with an average of 25 
billion USD
44
; there are firms dating back to the XVII century and firms which were founded 
no longer than ten-years ago; there are firms with a large set of products acting in different 
                                                          
38
 Some relevant information is not accessible for some firms, such as organic vs. external growth source. 
39
 There are 130 units outstanding as each sample unit is a company’s financial figures for a specific year. 
40
 See Appendix 9.8 for the list of firms comprising the sample and respective headquarters’ country. 
41
 According to the IMAP Healthcare report 2011. 
42
 As a result of the growth patterns of branded pharmaceutical products’ alternatives (e.g. generics or biosimilars) 
this sample might be unrepresentative of the industry population within some years. Also, conclusions withdrawn 
from this research are not generalizable to the pharmaceutical industry, as they are only tailored to branded 
pharmaceutical firms – judgment sampling may curtail the generalizability of the findings (Sekaran, 2010). 
43
 See Appendix 9.9 for a thorough analysis and description of the selected sample. 
44
 Figures are presented in US dollars - the majority of selected firms presented their financial statements 
in this currency. Firms presenting in USD: 13; EUR: 6; CHF:3; GBP: 2; DKK: 2. 
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therapy areas and firms relying solely on few therapy areas.  The collected data helps to build 
a database in SPSS which comprises 76 variables and 130 sample units – consists in one of 
the contributions of this research
45
.   
6. Results 
This section starts with a ROA breakdown of branded pharmaceutical firms, explaining 
major differences and similarities between Europe and the US (6.1). Next, it is tested whether 
country or region and firm size hold a significant correlation with ROA (6.2). Afterwards, it is 
tested which different strategic choices hold correlation with ROA components (6.3).  
6.1 ROA breakdown in Europe- and US-based firms (RQ.1): 
As it is shown in figure 3, overall ROA average levels for US- and European-based 
branded pharmaceuticals do not differ considerably and, thus, a thorough analysis of ROA 
components must be performed considering region-averages for the 26 sample firms.  
 
Figure 3: Operating profitability in branded pharmaceuticals: US and European firms’ year averages 
Starting with gross sales margin (GSM), region averages are the same both in 2007 
(0.75) and 2011 (0.75)
46
, although the US average presents higher GSM variance throughout 
the period. Regarding firms’ GSM rankings throughout the studied period, US firms appear 
mostly in the extremes, presenting firms with either the highest
47
 or the lowest
48
 GSM. 
Considering country averages for the studied period, Ireland and Denmark present the highest 
                                                          
45
 Appendix 9.10 provides a short version of the database, showing these research’s most important ratios. 
46
 Appendix 9.11 provides a GSM split between region averages for the period 2007-2011. 
47
 BIOGEN IDEC is the “sample leader” in 2008, 2010 and 2011 and CELGENE in 2007 and 2009. 
48
 In 2007, 2009, 2010 and 2011, the group of six companies with lower GSM is comprised by, at least, 
four US companies. BAXTER (0.50) and ABBOTT (0.58) present the lowest five-year GSM average.  
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GSM average while Germany and Belgium present the lowest level. GSM is influenced by 
two major factors: efficiency on managing variable costs and pricing. The sovereign debt 
crisis has led governments and public companies to constantly reduce their budgets, thus 
pressuring their suppliers’ prices. The Euro members have been the most influenced ones and 
this pattern is visible in the studied sample, since firms’ presenting lower levels of GSM are 
firms based in the Euro zone (Germany, Belgium and France). Thus, pricing pressure is a 
relevant determinant of a firms’ GSM, although it is not the only explanatory factor. To sum 
up, GSM is not a differentiating factor in ROA disparities among regions. 
Regarding operating leverage, US-based firms’ average present a lower degree of 
operating leverage (DOL) than European firms in all studied years
49;50
. US firms show 
higher ability on managing fixed-cost structures, presenting lower fixed-to-variable cost 
level – i.e. if European and US firms hold similar fixed costs (FC) levels, efficiency is higher 
in the latter. Rising cost pressures and patent expiry force many firms to reduce FC in order to 
maintain their position in the market. Firms are investing in the centralization of several 
functions – such as accounting– in one or few corporate centers
51
. Also, some firms are 
outsourcing their non-core-functions, such as information technologies or accounting, or even 
R&D (early-stage pipeline functions). If total fixed costs are divided into selling, general and 
administrative (S,G&A) and Research and Development (R&D), European firms, on average, 
present a greater level of S,G&A over FC (67% for the studied sample) than US firms (62%). 
Firms with the least of their costs in R&D are based in Ireland (23%) and Germany (27%), 
whilst biggest investors are based in Belgium (41%), Switzerland (39%) and the US (38%). 
Concerning assets turnover (AT), in 2007 and 2008 US-based firms’ region average is slightly 
                                                          
49
 Appendix 9.12 provides a 1/DOL split between region averages for the period 2007-2011. 
50
 GILEAD is “sample leader” in 2008, 2010 and 2011, with 1/DOL of 0.64, 0.60 and 0.65 respectively, i.e. 
it is the company that presents lower operating risk-levels throughout the sampled period. 
51
 Although it might represent a great cost cut, the efficacy of shared services centers (SSC) might be 
criticized, since some analysts argue that its benefits do not overcome its pitfalls – almost all firms in the 
sample possess at least one shared services center. 
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higher, whilst from 2009 onwards European-based region average present higher average 
levels – the gap between both regions increases as time passes
52
. The best firms managing 
size
53
 are Danish: LUNDBECK and NOVO NORDISK. Whilst the first presents AT year levels 
between 0.78 and 0.98, the second presents AT year levels between 0.88 and 1.03. Hence, 
Danish firms present higher AT averages in the studied period, whilst firms based in Belgium 
(0.36) and France (0.38) present the lowest AT averages – European-based firms appear in 
both the extremes of the AT average ranking. Segmenting AT analysis into short-term and 
long-term, inside Europe, Danish firms present the highest fixed assets turnover (FAT) - long 
term - and a medium-level IT inventory turnover (IT) – short term
54
; whilst firms based in 
Ireland present a low FAT and the second highest IT. Region-wise, US firms present higher 
average FAT whilst European firms show higher average IT. Also, US firms present 
shorter average operating cycles, i.e. it takes more time for European firms to transform their 
inventories in cash. However, European firms take more time paying to their suppliers (higher 
APP) and, consequently, present smaller CCC
55
. To sum it up, European firms present 
higher AT due to their greater ability to generate inventory rotation and smaller cash 
conversion cycles, whilst US firms hold a greater position in managing FAT.  
Table 1: Selected pharmaceutical firms’ limits for ROA and ROA components between 2007 and 2011 
Table 1 summarizes minimum, maximum and average values for ROA components. 
In a nutshell, GSM disparities are low between US and European averages, while European 
                                                          
52
 Appendix 9.13 provides an AT region average split between 2007 and 2011. 
53
 AT is used as a measure of size operating efficiency as it represents firms’ sales per asset owned. 
54
 Surprisingly, Danish firms present an activity ratio profile with similarities to the US firms. 
55
 Cash conversion cycle – Time elapsed to convert a purchase to a supplier in a receipt from a customer.  
Components 
US firms European firms Overall sample 
Limits Minimum Maximum Average Minimum Maximum Average Minimum Maximum Average 
Gross sales margin (GSM) 0.33 0.92 0.75 0.50 0.90 0.76 0.33 0.92 0.75 
Operating leverage (1/DOL) 0.06 0.96 0.35 0.07 0.90 0.28 0.06 0.96 0.32 
Assets turnover (AT) 0.23 0.82 0.58 0.24 1.03 0.60 0.23 1.03 0.59 
Return on assets (ROA) 0.02 0.42 0.15 0.02 0.35 0.13 0.02 0.42 0.14 
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firms present higher AT levels (mainly due to their ability in managing short-term assets and 
CCC), US firms present lower DOL levels (due to their lower proportion of S,G&A over FC). 
6.2 Country- and size-relationship with ROA (RQ.2 & RQ.3) 
In order to understand the relationship between headquarters’ country and ROA, 
correlation coefficients and a cluster analysis are performed
56
. There is not a significant 
correlation neither between country and ROA nor between region and ROA (RQ.2), 
contrary to the conclusions of Serrano, Molinero and Gallizo (2001) whose research entails 
firms from eleven European countries for a fourteen-year period that show correlation 
between country-membership and profitability. Hence, cluster analysis’ outcome - seven 
variables: size (total assets), age (years since foundation), ROA, R&D/REV, CR and EGS – 
highlights that firms grouped into common clusters do not belong to same countries
57
.  
Table 2: Characterization of the five groups obtained through cluster analysis – final cluster center values are presented 
Cluster one
58
 presents older low-to-medium-sized firms with the highest ROA. 
Diversification and EGS are medium-to-low. Cluster two
59
 comprises the lowest-sized and 
most recently formed firms, which present high average ROA. They are highly-specialized in 
few therapy areas, prioritize organic growth and invest a considerable part of sales in R&D 
activities. Cluster three
60
 entails the biggest firm, holding the highest diversification level and 
the highest EGS ratio, resulting in the lowest average ROA. Cluster four
61
 presents 
established big firms with high average ROA attained through great diversification levels and 
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 Appendix 9.15 provides the cluster analysis output from SPSS. 
57
 Appendix 9.16 provides all clusters information – output from SPSS. 
58
Cluster one: US - AMGEN, BRISTOL-MYERS SQUIBB, ELI LILLY; Germany – MERCK KGAA. 
59
Cluster two: Switzerland - ACTELION; US - ALLERGAN, BAXTER, BIOGEN IDEC, CELGENE, FOREST, 
GILEAD; Denmark - LUNDBECK, NOVO NORDISK; Ireland: SHIRE, WARNER-CHILCOTT; Belgium - UCB.  
60
Cluster three: US - PFIZER. 
61
 Cluster four: US - JOHNSON&JOHNSON, MERCK; Switzerland – NOVARTIS, ROCHE; France – SANOFI. 
Selected variables Cluster one Cluster two Cluster three Cluster four Cluster five 
Total Assets 31,483.75 7,877.91 164,476.00 94,069.60 59,424.75 
Nr. of years since foundation 158.25 50.50 162.00 71.20 73.50 
ROA 0.16 0.15 0.06 0.13 0.15 
R&D over Sales ratio 0.19 0.19 0.15 0.18 0.12 
Concentration ratio 0.28 0.64 0.18 0.21 0.20 
External growth source ratio 0.30 0.28 0.63 0.42 0.34 
Page|20 
 
external sourcing. Cluster five
62
 presents mid-to-high-sized firms which do not hold a 
considerably high diversification level and present the lowest R&D/REV average of the 
sample. Regarding size-correlation with operating profitability, although cluster three (highest 
asset level) presents the lowest ROA and cluster one (second lowest level of assets) presents 
the highest ROA, there is no significant correlation (-0.16) between ROA and firm size 
(RQ.3). Firm size only affects the way through which profitability is obtained, accurately 
agreeing with the conclusions obtained by Serrano, Molinero and Gallizo (2001).  
6.3 Strategic choices and ROA components (RQ.4, RQ.5 & RQ.6): 
A correlation analysis between strategic choices and ROA takes place
63
. The first 
variable is CR
64
 – RQ.4. There is a relevant correlation between CR and R&D over FC 
(0.46), i.e. firms with lower diversification levels present greater amounts of R&D as a 
percentage of the total FC they incur during a year. Nonetheless, there is not a significant 
relationship between levels of CR and DOL. However, CR presents a significant positive 
correlation coefficient with GSM (0.51). Focusing on the production and marketing of just 
one or two products diminishes a firm’s market potential and, thus, there is a negative 
correlation between CR and Sales (-0.63). However, that focus brings advantages to firms, as 
they specialize in the production of specific goods and, with the expertise acquired throughout 
time, they might be able to produce the same amount of units incurring in less variable costs, 
attaining higher levels of GSM. At last, there are significant correlations between CR and 
several activity ratios. In this sample, firms presenting higher levels of CR hold higher FAT 
levels (0.68), higher IT levels (0.48) and lower DTSI (-0.33) and ACP (-0.29). All this 
correlations lead CR to be positively correlated with AT (0.38), i.e. companies with higher 
“concentration levels” present greater AT levels – this can be observed as firms based in 
                                                          
62
Cluster five: US - ABBOTT; Germany – BAYER; UK – ASTRAZENECA and GLAXOSMITH KLINE.  
63
 Appendix 9.14 provides the correlation model obtained by the evidence gathered in Subsection 6.3. 
64
 See calculation and rationale in Subsection 5.1 – variables definition. 
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Germany and Denmark present the highest CR average (0.50) and, consequently, the highest 
AT average level (0.73). Therefore, there is a significant correlation between CR and 
ROA (0.22) (RQ.4), i.e. firms with less therapy areas are more specialized and obtain higher 
profitability per assets – for this sample, there is trade-off between diversification levels and 
profitability. This result goes against the findings of Guo & Cao (2012), who identified a 
positive relationship between diversification and profitability.  
Since the pharmaceutical industry is presenting an increasing level of consolidation and 
concentration, it is important to understand whether firms are benefiting from this process. 
EGS indicates how much of firms’ sales are generated by external sources
65
 - RQ.5. In this 
research sample, there is a negative correlation between EGS and proportion of R&D in terms 
of total FC (-0.27). Firms with greater EGS present much higher values of SG&A costs as a 
proportion of FC
66
. However, the correlation between EGS and 1/DOL is not significant, i.e. 
EGS levels cannot clearly relate to differences in DOL. Additionally, there is a significant 
negative correlation coefficient between EGS and GSM (-0.18). Firms with greater EGS often 
present higher sales levels ( =0.25), although that is surpassed by even higher COGS levels 
( =0.30), because firms have less control over their production processes. At last, there is a 
significant correlation between EGS and two activity ratios (FAT with -0.5 and IT with -0.16). 
Hence, firms with higher levels of internally generated sales present higher levels of FAT and 
IT and, consequently, higher levels of AT (0.37). Therefore, there is a negative significant 
correlation between EGS and ROA (-0.28) (RQ.5), as firms presenting higher EGS levels 
are poorer in managing current- and non-current assets turnover. This finding corroborates 
one conclusion drawn by Brealey, Myers & Allen (2011): mergers normally increase the 
operating margin, but the positive effect in ROA is offset by a great reduction in firms’ AT. In 
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 See Subsection 5.1. – Variables definition. 
66
 WARNER-CHILCOTT presents the highest level of SG&A as a proportion of FC (between 0.79 and 0.90 
in the period 2007-2011) and presents the highest EGS average level between 2009 and 2011. 
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this sample, German and Danish firms present the lowest average level of EGS (0.29) and, 
consequently, present the highest AT average level (0.73).  
At last, R&D over sales (R&D/REV)
67
 (RQ.6) is used as a proxy of investment (and 
risk). R&D/REV holds a significant correlation with 1/DOL (-0.24), because firms which 
invest more in R&D hold heavier cost structures, higher DOL levels and lower MS (-0.42)
68
, 
i.e. higher operating risk. Firms in the studied sample presenting higher levels of R&D/REV 
demonstrate higher GSM (0.45) – firms investing a greater part of their sales in R&D hold a 
higher probability of discovering a larger amount of new drugs and, thus, charge higher prices 
when they are holding new patents.  At last, R&D/REV and AT do not hold a significant 
correlation, as the level of firms’ investment in R&D is not directly related to the way firms 
manage their assets. Thus, there is a negative effect between R&D/REV and ROA (-0.18) 
(RQ.6), mainly because firms perform heavy investments with low expected outcome. 
Table 3: Correlation coefficients among strategic choices, ROA and ROA components (* - significant for 95% confidence level)  
Thus, firms holding lower product diversification levels present higher ROA (0.22) as 
result of an increasing GSM (0.51) and AT (0.38) (RQ.4). Firms presenting higher internally 
sourced sales present higher ROA (0.28) as a result of higher GSM (0.18) and higher AT 
(0.37) (RQ.5). Also, firms presenting higher R&D/REV show a greater ability to increase 
GSM (0.45), but the net effect on ROA is negative (-0.18) - cost structure becomes heavier 
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 See subsection 5.1. – Variables definition. 
68
 As companies have lower levels of 1/DOL ratio, their operating risk increases and their margin of 
safety diminishes – in this case the correlation between R&D/Revenue and Margin of Safety is -0.42. 
69
 Correlations presenting “*” refer to significant correlation coefficients for a confidence level of 95%. 
Correlation 
     Coefficients69 
Investment: 
R&D over sales 
Diversification: 
Concentration ratio 
Growth choices: 
External growth source 
Gross sales margin 0.45* 0.51* -0.18* 
Operating leverage -0.24* -0.04 -0.12 
Assets turnover -0.13 0.38* -0.37* 
Return on assets -0.18* 0.22* -0.28* 
R&D over sales N/A 0.45* -0.35* 
Concentration ratio 0.45* N/A -0.43* 
External growth source -0.35* -0.43* N/A 
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and DOL increases ( =0.24)70 (RQ.6), going against conclusions of Serrano & Mavarez 
(2011) who do not find significant correlation between strategic choices and profitability.  
Every firm in the sample presents a mix of CR, EGS and R&D/REV levels. However, 
firms with higher CR often present a higher R&D/REV (r=0.45) and lower EGS levels      
(r=-0.43). Firms with higher R&D/REV present lower EGS (r=-0.35). Thus, pharmaceutical 
firms can be identified in a continuum with two extreme points: big-sized, highly-diversified, 
highly co-operative firms or small-to-medium-sized, independent, not-diversified firms.    
Furthermore, this research gives insight that allows future researchers to perform a 
deeper analysis of overall strategy of big players, i.e. instead of performing a worldwide 
analysis, researchers are able to study individual firms’ operating profitability thoroughly.    
7. Conclusions 
This work project aims at studying operating profitability of branded pharmaceuticals. It 
tests correlation between profitability and strategic choices, profitability disparities as result of 
country and size differences and, profitability disparities between US and European firms.  
It addresses some of the most important pharmaceutical firms’ stakeholders: management 
teams – giving them insight on benefits and risks arising from different strategic choices; and 
investors and industry analysts – giving them insight about the relation between the 
pharmaceutical industry’s trends and operating profitability of branded pharmaceuticals.  
US and European firms present, on average, similar ROA in the period of 2007-2011. 
Gross sales margin (GSM) does not appear as a differentiating factor between them, as levels 
of gross profit per sales unit for both regions are similarly high. By the one hand, it was 
concluded that, on average, European firms consistently achieve higher assets turnover (AT), 
mainly due to their short-term asset management skills, while US firms achieve higher long-
term asset turnover. By the other hand, on average, US firms present lower operating leverage 
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 Correlation between R&D/REV and DOL. 
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(DOL) than European firms. Basically, there are differences between regions’ operating 
profile, but country-membership does not hold a significant correlation with ROA. Firm size 
does not hold a significant correlation with ROA. Variables concerning strategic choices were 
designed and their correlation with ROA was tested. Concentration ratio was used as a proxy 
to portfolio diversification; external growth source ratio was set as a growth choice measure; 
and R&D over sales as a measure of investment and risk. Diversified firms tend to present 
lower ROA; firms holding higher internally-sourced sales present higher ROA and; firms 
holding higher R&D over sales present lower ROA. Also, it was found that firms presenting 
higher diversification tend to hold higher externally-sourced sales and lower R&D over sales.  
The results of this research depended on its research design. They are valid for branded 
pharmaceuticals, but cannot be generalized for the whole industry, since the sample selected 
did not include generics firms. Knowing that the latter are becoming more and more relevant, 
a suggestion for future research is to develop studies for the non-branded segment. Also, 
answering the same research questions in a wider range of firms; introduce new strategic 
variables and enhance insights of this industry’s operations; or perform thorough analysis of 
individual firm’s strategies. Moreover, profitability in branded pharmaceuticals is still a key 
topic in the healthcare scenario, as these firms present higher potential to discover new drugs - 
it is vital to study how these firms can keep helping patients without losing profitability.  
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9. Supplemental Information - Appendices 
This section includes all appendices and support information or data about the 
research that are not necessarily needed in order to understand the report assumptions and its 
main findings, but that may aid the reading. It is entailed by small analyses, graphs, figures 
and part of the developed database. This supplemental information is presented by the same 
sequence as the appendices are mentioned in the research.  
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Appendix 9.1: 
Global pharmaceutical industry sales’ growth rate evolution between 2003 and 2011 
The worldwide pharmaceutical industry presents a great growth rate decline between 
2003 and 2011, although growth rates of emerging markets might push up growth rate levels 
in a near future. 
 
Source: IMS Healthcare Market Prognosis, May 2012. 
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Appendix 9.2.a: 
“Healthcare industry” breakdown by sectors - brief description  
 
Source: Datamonitor Healthcare and Firms’ annual reports 
 
 Branded prescription pharmaceutical products are comprised by all products 
for which pharmaceutical companies hold (or already have held) official patents 
which provide them the exclusive right to produce and marketing such products. 
They are comprised by four major categories: small molecules, biologics, 
vaccines and emerging therapies (see appendix 9.2.b for brief descriptions). 
 Generics comprise all “me-too” drugs developed by companies which do not 
hold (and never have held) official exclusivity patents. Although there are 
companies which solely focus in the production of these types of products, more 
and more big brands are investing in this type of diversification in order to reduce 
risk and increase market coverage. 
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 Biosimilars present higher levels of profitability but also higher-risk profile than 
Generics. They present lower development costs and lower risk of pipeline failure 
when directly compared to branded products. 
 
Appendix 9.2.b: 
Prescription pharmaceutical market breakdown by sectors  
 
Source: Datamonitor Healthcare and Firms’ annual reports 
 
 Small molecules are easier to manufacture and market than other sub-segments in 
branded pharmaceuticals. It is decreasing in importance, although some 
companies might still rely on it in order to develop their strategic objectives, since 
it still presents the subsector with the largest market size and a high operating 
profit margin. Small molecules are related to primary-care products, and some 
examples of areas where small molecules play a vital role are: Central nervous 
system diseases, cardiovascular, metabolic, and infectious diseases. 
 Biologics are more specialized when compared to small molecules, since they 
represent niche products for secondary care markets – what represents a lower 
level of risk for the biologics’ production holder, since there is the need to hold the 
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specific/rare level of expertise to be able to produce such pharmaceuticals. 
Examples of biologics-dependent areas are Oncology, Injectable drugs and 
Monoclonal antibodies. 
 Vaccines entail all biological products that aim to enhance and strengthen the 
immune system in what concerns fighting specific diseases. 
 With the shift towards patient-focus and cross of knowledge between medical 
disciplines pharmaceutical firms are, more and more, focusing on offering 
integrated Disease Management Solutions (not offering a whole array of 
products and treatments but also focusing in prevention). Specialists expect that 
implementing these programs will have positive impacts not only in the 
effectiveness of the practices but also on healthcare savings for payers. The 
provision of these types of solutions has become vital for companies playing in 
specific chronic diseases’ markets that require close management by healthcare 
providers.    
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Appendix 9.3: 
Summary of the whole literature review performed: 
Author Paper Objectives 
Main 
Variables Sample Period Conclusions 
CAYSSIALS 
(2010) 
The financial position 
of SMEs in 
manufacturing: a 
comparison between 
six European countries 
To analyze the 
financial structure 
of small and 
medium 
manufacturing 
enterprise (SMME) 
Profit margin, 
operating margin, 
Equity-to-assets,  
Bank loans as 
proportion of 
Total non-current 
liabilities, etc 
Financial data from 
small and medium 
manufacturing 
enterprises (SMME) 
in six European 
firms obtained from 
the BACH database. 
1994-2006 
1. Financial structure of 
SMME has strengthened 
throughout the period of 
analysis; 2. There is a great 
disparity in what concerns 
profitability; 3. profit 
margins for SMME present 
lower levels than large 
firms. 
COLLIER ET. 
AL (2004) 
An example of the use 
of financial ratio 
analysis: the case of 
Motorola 
To build a ratio 
analysis for the 
Motorola 
Corporation, 
comparing the 
results to industry 
averages for 
different business 
segments. 
Current ratio, 
quick ratio, 
average collection 
period, inventory 
turnover, fixed 
assets turnover, 
assets turnover, 
debt ratio, debt-to-
equity ratio, times 
interest earned, 
gross profit 
margin, net profit 
margin, ROI, 
ROE. 
Motorola financial 
statement figures 
1999-2002 
Performing financial ratio 
analysis becomes difficult 
when companies do not 
fall into a single industry, 
and that conclusions might 
be diverse if different 
industries are considered 
as benchmark. 
DAVIDSON & 
GREBLOV 
(2005) 
The pharmaceutical 
industry in the global 
economy 
To draw a global 
overview of the 
pharmaceutical 
industry - most 
important trends, 
most important 
players and the 
preponderance of 
the US firms in the 
overall market. 
N/A - This is a 
purely descriptive 
paper. 
Information for the 
top 15 firms in what 
concerns worldwide 
consolidated 
prescription sales 
1995-2004 
This paper summarizes the 
main industry trends 
occurring in the 
pharmaceutical industry 
between 1995 and 2004, 
highlighting the M&A 
activity, portfolio 
management, therapy 
areas, investment in 
different market segments 
and growth sales. 
GUMUS & 
CELIKKOL 
(2001) 
Data envelopment 
analysis: an augmented 
method for the analysis 
of firm performance 
To develop an 
alternative firm 
performance 
measurement 
method through a 
Data envelopment 
analysis (DEA) 
Current ratio, 
acid-test ratio, 
debt-to-equity 
ratio, equity 
multiplier, net 
profit margin, 
ROA and ROE 
Financial data from 
manufacturing firms 
listed on the Istanbul 
Stock Exchange 100 
Index 
2005-2008 
Both types of analyses are 
complementary 
performance measurement 
methods and, thus, data 
envelopment analysis 
(DEA) is a valid 
performance predictor. 
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Author Paper Objectives 
Main 
Variables Sample Period Conclusions 
GUO & CAO 
(2012) 
An analysis of the 
degree of 
diversification and firm 
performance 
To re-examine the 
relationship 
between the degree 
of diversification 
and firm 
performance. 
Portfolio 
diversification and 
firm performance 
(Tobin q's, ) 
All firms with 
available data on the 
Compustat Industry 
Segment Database 
1996-2002 
1. There is a significant 
positive relationship 
between firm performance 
and diversification. 2. 
Diversification’s benefits 
get smaller if firms engage 
in more than three different 
industries. 
HOSSAN & 
HABIB (2010) 
Performance 
evaluation and ratio 
analysis of 
Pharmaceutical 
Company in 
Bangladesh 
To perform a 
thorough financial 
ratio analysis of 
two pharmaceutical 
companies in 
Bangladesh and 
expose it 
graphically. 
Liquidity ratios, 
Asset management 
ratios, profitability 
ratios, debt 
coverage ratios 
and market value 
ratios 
Beximco 
Pharmaceuticals' 
and Square 
Pharmaceuticals' 
financial statement 
figures present in 
this companies' 
annual reports 
2007-2008 
Summing it up, Beximco 
shows to hold better 
overall performance levels 
than Square. 
LEWELLEN 
(2004) 
Predicting returns with 
financial ratios 
To examine the 
relationship 
between dividend 
yield prediction 
and market returns. 
Dividend yield, 
Book-to-market 
value and  
Earnings-price 
ratio 
Companies listed in 
NYSE  
1946-2000 
Market returns can be 
explained by dividend 
yield prediction to a great 
extent. 
MAJUMDER, 
Md.; 
RAHMAN, 
Mohammed 
(2011) 
Financial Analysis of 
Selected 
Pharmaceutical 
Companies in 
Bangladesh; Journal of 
Biology, Agriculture 
and Healthcare 
The study is 
designed to 
achieve the 
following 
objectives: 
(i) To assess the 
financial 
performance of the 
selected 
Pharmaceuticals 
firms. 
(ii) To test the 
financial strengths 
and weaknesses of 
selected 
Pharmaceuticals 
firms. 
(iii) To pinpoint 
the causes of poor 
financial 
performance and 
suggest some 
measures to 
overcome the 
problems. 
Profitability ratios, 
Liquidity ratios, 
Activity ratios and 
Solvency ratios 
Financial data from 
9 "A" and "B" 
category 
Bangladeshi 
Pharmaceutical 
companies 
2005-2008 
Profitability, liquidity and 
solvency levels of most of 
the analyzed companies 
have been deteriorating 
over time and some of 
those companies are near 
bankruptcy levels. 
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Author Paper Objectives 
Main 
Variables Sample Period Conclusions 
MARQUES, 
João Pedro 
(2011) 
Return on Equity: A 
comparison between 
companies in Portugal 
and Brazil: Similarities 
and Differences; 
NOVA Thesis 
To understand the 
differences and 
similarities among 
companies based in 
Portugal and in 
Brazil - with a 
bigger incidence in 
the financing 
decisions. 
ROE, Financial 
Leverage (cost of 
debt and 
proportion of 
debt), Effective 
tax rate 
Information present 
in the annual reports 
of companies listed 
in the Euronext 
Lisbon and (PSI20) 
and Ibovespa 
(Brazil). 20 
Portuguese 
companies and 60 
Brazillian 
companies in the 
sample. 
2005-2010 
Portuguese firms take 
more advantage from 
financing decisions (since 
they face lower corporate 
taxes and interest rate 
levels), Brazilian firms 
benefit the most from their 
investing decisions. 
PARÉS, 
António (1980) 
The return on equity 
decomposition 
(ROED) and its 
importance to Financial 
Statement Analysis; 
Journal of Business 
Finance and 
Accounting 7,3 (1980) 
To highlight the 
pitfalls regarding 
the use of financial 
ratios and to 
propose an 
empirical model to 
measure firm’s 
financial leverage 
effects on 
corporate 
profitability. 
ROE, ROA, 
Financial 
Leverage 
Compound 
Virtual situations 
Virtual 
situation 
The ROED model, based 
on accounting information, 
allows a more precise 
description of the 
"leverage effect" and its 
impact on corporate 
profitability. 
RIVAUD-
DANSET ET. 
AL (2001) 
Comparison between 
the financial structure 
of SMEs and that of 
large enterprises (LES) 
using the BACH 
database 
To compare 
financial structure 
of small and 
medium enterprises 
(SME) and large 
enterprises (LES) 
Leverage, reserves 
rates, short-term 
fin. Debt, cover 
rate of K emp., 
liquid capital 
requirement, cash 
flow capacity, 
leverage impact, 
gross profitability, 
mark-up ratio, 
solvency among 
many others. 
Financial data from 
the manufacturing 
industry of nine 
countries obtained 
from the BACH 
database. 
1990-1996 
1. SME show higher 
efficiency of capital 
employed; 2. The 
importance of short-term 
debt seems to be higher for 
SME than for LES; 3. 
There is no proven link 
between financial structure 
choice and profitability. 
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Author Paper Objectives 
Main 
Variables Sample Period Conclusions 
SERRANO, 
Eugenia Suaréz; 
MAVAREZ, 
Enzo Piña 
(2011) 
R&D, Risk and 
Performance in the 
Spanish 
Pharmaceutical 
Industry: A strategic 
group analysis 
To provide 
evidence that 
different strategic 
choices affect the 
performance of the 
company, as well 
as its R&D 
efficacy and the 
level of risk to 
which they are 
exposed. Most 
importantly, to 
provide evidence 
that grouping 
pharmaceutical 
companies into 
different clusters 
can be a good tool 
to understand the 
effect of different 
strategic decisions. 
Operating Profit 
Margin, ROE, 
ROA 
 
Size of the 
company, 
International 
vocation, degree 
of diversification, 
economies of 
scale. 
Financial data from 
45 medium and 
large pharmaceutical 
laboratories with 
manufacturing 
capabilities in 
Spanish soil (either 
foreign 
multinational 
companies or 
Spanish-based 
pharmaceutical 
companies) 
2000-2003 
1. Companies are grouped 
into three major clusters: 
national capital, foreign 
capital and mixed capital; 
2. The adoption of 
different strategies does 
not explain differences in 
firms’ profitability levels. 
SERRANO, 
MOLINERO & 
GALLIZO 
(2001) 
Country and size 
effects in financial 
ratios: A European 
perspective 
To study country- 
and size-effects on 
financial ratios 
Size, Country, 
Fifteen Financial 
Ratios and 
Macroeconomic 
indicators: GDP, 
Unemployment. 
Financial data from 
many industries of 
eleven countries 
obtained from the 
BACH database. 
Fourteen 
year 
period 
before 
2000 
Profitability disparities are 
not affected by size. 
Differences in profitability 
arise when country-
features are compared - 
three strategic groups were 
discovered: Latin, 
Scandinavian and German. 
SOLIMAN 
(2008) 
The use of DuPont 
analysis by market 
participants 
Test whether 
information 
contained in 
DuPont analysis 
has a correlation 
with stock market 
returns, 
considering a ROA 
breakdown into 
two multiplicative 
factors: operating 
profit margin and 
assets turnover. 
ROA, OPM, AT,  
ROE, Return on 
non-operating 
assets, Market 
adjusted returns 
38,716 firm-year 
observations 
available in I/B/E/S 
and Compustat 
1984-2002  
It is concluded that DuPont 
components are a valid 
source of information 
about the firm’s operating 
characteristics and, 
consequently, they are 
good predictors of firm’s 
future earnings. 
 
 
Page|35 
 
Author Paper Objectives 
Main 
Variables Sample Period Conclusions 
TAVAKOLLI 
ET. AL (2010) 
New method to 
evaluate financial 
performance of 
companies by fuzzy 
logic: case study, drug 
industry of Iran 
To create a fuzzy 
logic method 
which helps 
investors evaluate 
firms’ performance 
through ranking of 
firms included in 
each industry. 
Quick ratio, ROE, 
Financial leverage, 
ROI, Current ratio, 
P/E 
Financial data from 
nineteen 
pharmaceutical 
firms listed in the 
Tehran Stock 
Exchange 
2007 
Using fuzzy logic in ratio 
analysis is simple but it 
adds value to the existent 
literature. Also, according 
to the established criteria, 
companies X18, X6, X4 
and X14 are the best 
performing ones (they are 
not identified). 
UTRILLA ET. 
AL (2012) 
How does strategic 
choice affect business 
results? A case study of 
mutual guarantee 
societies 
Examine the 
relationship 
between diverse 
strategic choices 
and Spanish 
mutual guarantee 
societies’ (MGS) 
performance 
Number of offices, 
production 
efficiency, 
operating 
efficiency, income 
from assets, 
concentration by 
sector, 
concentrating of 
operating 
receiving 
guarantees and 
other. 
22 Mutual 
Guarantee Societies 
in Spain  
1997-2009 
The authors group all the 
22 companies in four 
strategic groups. 
Moreover, they conclude 
that MGS performance is 
affected by differences in 
strategy. 
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Appendix 9.4: 
Pharmaceuticals’ profile: industry averages comparison 
In order to perform this industry’s analysis, it is imperial to compare its ratios’ 
averages values with other industries’ averages. Therefore, a comparison between 
pharmaceutical industry averages and automotive, telecommunications and retailing was 
performed. These industries were specifically chosen due to their particular characteristics: 
telecommunications’ industry is similar to the pharmaceutical industry as they hold high entry 
barriers due to the high initial investment level; retailing presents a profile which differs from 
pharmaceuticals’ as those firms present lower margins and higher turnovers – exactly the 
opposite profile of what is expected from the pharmaceutical industry; and automotive 
because it presents low margins, relatively high turnover but a relevant initial investment. 
Hence, this group of three industries seems suitable to understand in which type of profile the 
pharmaceutical industry fits, as they present highly diverse profiles. 
The pharmaceutical industry has the lowest level of asset turnover – due to the great 
investment that these firms have to perform in order to generate sales - and the lowest 
receivables turnover – due to the high average collection period presented by this industry’s 
firms, as their major customers are public entities. Regarding GSM, this industry shows a 
high average, being surpassed only by the telecommunications’ industry average. Although 
telecommunications show higher GSM, their OPM average is lower than pharmaceuticals’, 
showing that telecommunications’ firms hold heavier fixed-cost structures. Regarding 
leverage, this industry is the one presenting the lowest debt-to-assets ratio average – more 
conservative, more equity financed (presenting 16.6%, while the second place presents 
41.9%) – and the debt risk is low compared to the other three industries’ profile. Concerning 
profitability itself, it is possible to see that, for industry averages of the last five years, 
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pharmaceutical presents the highest value of ROA and ROE. However, the downward trend 
in pharmaceutical firms’ sales growth rates is noteworthy as the pharmaceutical industry 
presents the lowest ROE for 2011 and the second lowest ROA level for the same year. 
Therefore, it is possible to identify the pharmaceutical industry as a highly profitable business 
which has been presenting a relevant slump in its growth rates in the last few years, 
maintaining its relatively high margin levels and demonstrating low turnover ratios. 
REUTERS (2011 figures) – 
Industry averages: 
Pharmaceutical Telecommunications Retailing Automotive 
Asset Turnover 0.39 0.53 1.73 0.71 
Gross Sales Margin 0.62 0.84 0.37 0.22 
Operating Margin 0.14 0.11 0.73 0.11 
ROE   7.45 30.56 13.36 13.46 
ROE - last 5 years 14.77 7.92 13.22 13.88 
ROA  4.35 3.98 7.13 6.14 
ROA - last 5 years 9.75 4.01 6.86 4.95 
Beta (Level of Debt risk)  0.59 0.53 0.69 1.09 
Debt to Assets Ratio  0.166 0.605 0.419 0.971 
Receivable Turnover 2.62 4.92 54.66 15.21 
 
Source: Reuters 
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Appendix 9.5: 
Enlarged SWOT analysis of the pharmaceutical industry in the developed countries 
(namely in Europe and in the US) 
Although it has been identified that the pharmaceutical industry’s overall profitability 
has been decreasing in the last few years, it is possible to identify two types of firms in this 
industry with differentiated growth patterns in the XXI century: firms based in developed 
countries and firms based in developing countries. Although most firms act globally, through 
marketing of products both in developed and in developing countries, firms based in 
developed countries focus their sales in developed countries (specially its headquarters’ 
country) and firms based in developing countries focus their sales in developing countries. 
Hence, firms based in developing countries have been benefiting more from the improvement 
noted in such countries, both in social and economical terms, with the levels of healthcare 
expenditure increasing at double-digit figures. Firms based in developed countries have been 
facing difficulties in maintaining sales’ growth rates which they presented before, as 
healthcare expenditure’s growth rate is contracting in most developed countries – that is one 
of the reasons why most Big Pharma and Mid Pharma firms are investing in emerging 
markets, in order to reach new potential customers and clients and take advantage of the great 
growth conditions which such countries are presenting.  
Considering that this research sample is comprised by firms based in developed 
countries, it is paramount to develop a SWOT analysis in order to identify major strengths and 
weaknesses from the branded pharmaceutical industry as whole but, most importantly, to 
identify possible opportunities and the most dangerous threats which these firms are facing as 
result of the current market conditions. 
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As only some of the sample firms present business units focused in generics 
production (BAXTER, FOREST, SHIRE, UCB  and more recently, NOVARTIS, JOHNSON & JOHNSON, 
BAYER AND SANOFI) and most of them are not relevant in global prescription sales terms, this 
firms still present significantly high GSM (S), although there has been a downward trend, as 
pricing pressures rise (T) and patent expiries come closer (T). However, these firms benefit 
from their solid position in the market and from their brand equity (S) in order to tackle 
potential competition from generics-focused firms (T). By having relevant asset structures 
which allow them to sustain value chains distributed throughout several countries (S), Big 
Pharma and Mid Pharma firms can leverage this factor in order to enhance their position in 
new markets through different types of diversification (O) - as the pharmaceutical industry is, 
more and more, becoming a global industry (O). Also, as there has been occurring a strong 
consolidation in the market (O), through M&A activity and strategic partnerships, Big Pharma 
and Mid Pharma firms can leverage each others’ resources and capabilities in order to achieve 
scale economies and, ultimately, better outcomes (product) and results (profitability). The 
population ageing, increase of average life expectancy and technological advancement 
constitute opportunities which these firms might take advantage of (O), although regulatory 
constraints (T) have grown bigger in the last few years, limiting some of these firms’ activities 
or increasing the bureaucracy level in specific stages of the production or marketing of 
pharmaceutical products. 
Apart from all the mentioned characteristics, there are some factors which branded 
pharmaceutical firms are not able to avoid when performing their business. This is a business 
where great investment in R&D and Marketing is needed (W), creating a great reliance of 
firms in their heavy fixed cost structure, generating low assets turnover (W) since 
pharmaceutical firms need a great structure in order to generate sustained levels of sales. Also, 
as health is a public concern, government and public entities are presented as pharmaceutical 
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firms’ major customers (however, in the US and in other specific countries, healthcare 
expenditure does not rely so heavily on public entities), what could constitute a barrier to 
firms’ liquidity and to damage their operating cycles.  
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Appendix 9.6: 
Porter five forces’ analysis of the branded pharmaceutical industry 
 
Competitive Rivalry: 
 There is a high level of competition among the strongest players in the market. 
Although some of them do not rely in the same therapy areas, competition is truly high in the 
most relevant therapy classes of the pharmaceutical industry: for instance, in Oncology, which 
presents 62.2 billion USD worldwide sales in 2011 - therapy class with highest sales volume 
in this year - Roche is the sample leader in sales’ terms, presenting 21.3 billion USD 
worldwide sales in 2011, around 35% of the market, and the second biggest oncology 
products seller in the sample is Novartis, presenting 10.7 billion USD sales in 2011, with 
around 14% of the Oncology market. Great part of the market share in this segment belongs 
to these two firms, although the remaining 50% are well disputed among several firms. 
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Respiratory Agents registered 39.4 billion USD worldwide sales in 2011, being the second 
therapy class with highest sales volume in 2011. The sample leader is GlaxoSmith Kline 
presenting 11.9 billion USD worldwide sales in 2011 (around 30% of the market share) and 
the sample second place presents 4.4 billion USD worldwide sales in 2011 (around 10% of 
the market share). Thus, in each therapy area there a significant number of players which 
fiercely fight for that specific segment market share – but the pharmaceutical industry 
presents even higher competition at local level.  
Bargaining Power of Suppliers: 
 Although there is a great competition in the marketplace, a great part of the worldwide 
pharmaceutical industry sales is led by a small number of big players in the market. This fact 
empowers firms to sustain higher bargaining power with suppliers, not enabling them to 
sustain constant variable cost increases, namely in raw materials or in specific operating 
expenses. Summing it up, there are big players in the market which contain internationally 
integrated value chains, enabling them to look and make business for the best suppliers, either 
looking for quality or for good prices. 
Bargaining Power of Customers: 
 A great part of pharmaceutical firms’ customers are government entities. By the one 
hand, firms cannot negotiate with customers with the same level of efficiency as they do with 
suppliers, as public entities are able to bargain more strongly. By the other hand, as 
governments of the most developed countries are suffering from the consequences of the 
financial crisis from 2008 and the sovereign debt crisis from 2011, there is great pressure to 
reduce public expenditure as much as possible. Therefore, public entities are reinforcing 
pricing pressure measures, what leads to a drop in the margin which pharmaceutical firms are 
able to extract from their business. Hence, although big pharmaceutical firms can exert some 
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power in order to bargain with public entities with the aim of avoiding a sudden reduction in 
their margins, public entities have strict budget restrictions to follow – what can lead a great 
amount of prescription sales to be channeled to the generics market in the upcoming years.   
The Threat of Substitution: 
 Considering the aforementioned pressure on prices developed by public entities as 
well as the great number of patents coming closer to expiry, generic products are becoming a 
real threat to branded-products, increasing this industry’s level of substitution and augmenting 
the need of branded-products to develop actions in order to show what are their benefits 
compared to generics-market. More than ever firms have to invest in R&D (and not only 
invest, but obtain good levels of R&D efficiency) and in Marketing to create a strong point-
of-differentiation (POD) towards generics in order to create sustainable competitive 
advantages over those low-priced products. 
The Threat of New Entrants: 
 There are several barriers to the entry of new players in the market – ranging from 
regulatory constraints to the initial investment level needed in order to develop business in the 
pharmaceutical industry. Hence, the threat of new entrants is low in this industry. However, as 
the potential of generics market is becoming clearer and clearer, the biggest threat in this 
industry is the entry of established firms in new markets, namely the hard-to-make generics 
one, which is the market presenting the highest long-term potential in the whole 
pharmaceutical industry. 
Overall level of attractiveness: 
Although this industry is highly innovative and profitable, it does not seem to present 
a high level of attractiveness to the entry of new players in the branded pharmaceutical sector. 
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Big-brands are facing difficult challenges since the generics market boom has started and, 
although these firms are gaining market share, they will always depend upon new discoveries 
from big players and there already are a great number of generics’ producers in the 
marketplace, indicating that most of the shifts shaping this industry in the upcoming years 
might be developed by incumbent firms. Apart from that, the big initial investment and the 
regulatory constraints present strong barriers to entry. 
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Appendix 9.7: 
Sample selection model 
 The sample selection was performed through a judgmental sampling and it comprises 
three different criterions:  
 
 
 
 
 
 
 
This research’s population: Multinational branded pharmaceutical 
companies based in developed countries 
First criterion: 
Pharmaceutical 
firms based 
either in 
European 
countries or in 
the US. 
Sample 1: Top 20 Multinational branded pharmaceutical 
companies based in the US and Top 20 multinational branded 
pharmaceutical companies based in European countries. 
Second criterion: 
Top 20 
prescription 
sales’ 
pharmaceutical 
firms from each 
region  
Final Sample:  
- Top 13 multinational branded pharmaceutical companies based in 
the US presenting required information; 
- Top 13  multinational branded pharmaceutical companies based in 
European countries presenting required information. 
 
 Third criterion 
Choose only branded 
pharmaceutical firms which 
present required information  
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Appendix 9.8: 
Companies summarized information: 
Logo Company Country 
Year of 
Foundation 
Website 
 Abbott United States 1888 www.abbott.com 
 Actelion Switzerland 1997 www.actelion.com 
 Allergan United States 1948 www.allergan.com 
 Amgen United States 1980 www.amgen.com 
 AstraZeneca United Kingdom 1999 www.astrazeneca.com 
 Baxter United States 1931 www.baxter.com 
 Bayer Germany 1863 www.bayer.com 
 Biogen Idec United States 2003 www.biogenidec.com 
 Bristol-Myers Squibb United States 1887 www.bms.com 
 Celgene United States 1986 www.celgene.com 
 Eli Lilly United States 1876 www.lilly.com 
 Forest United States 1954 www.frx.com 
 Gilead United States 1987 www.gilead.com 
 GlaxoSmith Kline United Kingdom 2000 www.gsk.com 
 Johnson & Johnson United States 1886 www.jnj.com 
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Logo Company Country 
Year of 
Foundation 
Website 
 Lundbeck Denmark 1915 www.lundbeck.com 
 Merck & Co. United States 1917 www.merck.com 
 Merck KGaA Germany 1668 www.merckgroup.com 
 Novartis Switzerland 1996 www.novartis.com 
 Novo Nordisk Denmark 1923 www.novonordisk.com 
 Pfizer United States 1849 www.pfizer.com 
 Roche Switzerland 1896 www.roche.com 
 Sanofi France 2004 www.sanofi.com 
 Shire Ireland 1986 www.shire.com 
 UCB Belgium 1928 www.ucb.com 
 Warner-Chilcott Ireland 1968 www.wcrx.com 
 
Brief company description: 
Abbott Laboratories Ltd. 
Abbott is a US-based diversified healthcare company founded in the XIX century and 
belonging to the Big Pharma set of companies. In 2011 it presented around 90,000 employees 
worldwide and sales level of around 38 billion USD, being present in the 2011 top 10 
pharmaceutical firms in what concerns worldwide prescription sales. Besides being one of the 
most diversified healthcare companies in the world, it is one of the companies which invest 
more in the “externalization” of its functions (M&A, strategic partnerships or outsourcing, 
with greater incidence in the first). The therapy areas of greater importance in Abbott’s sales 
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are immunology and inflammation, cardiovascular, infectious diseases and central nervous 
system diseases, and it does not sell generic or biosimilar products. 
 Actelion Pharmaceuticals Ltd. 
Actelion is a Swiss Mid Pharma company founded in 1997 presenting around 2,500 
employees in 2011 and sales level of around 2 billion USD. This company is highly 
specialized - almost exclusively focused in selling cardiovascular products and solutions 
(which accounted for more than 90% of its total 2011 prescription sales level). It does not sell 
generic or biosimilar products. Although the company has presented a low level of 
outsourcing, strategic partnerships or M&A activity occurrence throughout its existence, it has 
been presenting good growth rates in the last few years, indicating that this might be a serious 
player, taking into considering the current trends in the pharmaceutical industry. 
Allergan Inc. 
Allergan is a US-based multi-specialty Mid Pharma company founded in 1948, presenting 
around 8,500 employees and sales level of almost 5.5 billion USD in 2011. It presents a 
medium-to-low diversification level, being focused mostly in central nervous system diseases. 
It is a highly innovative firm, presenting medium-to-high reliance of its sales in externally 
developed products (M&A, strategic partnerships and outsourcing), not presenting sales of 
generic products.   
Amgen Inc. 
Amgen is a US-based Mid Pharma company founded in 1980 and presents, in 2011, around 
18,000 employees worldwide, sales level of around 15 billion USD and total assets around 49 
billion USD. This company does not sell generic or biosimilar products, presenting a 
medium-to-low diversification level, focusing its sales in three therapy areas: oncology, 
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immunology and inflammation, and hematology. Besides, it presents a low level of externally 
sourced products.  
 AstraZeneca 
Founded in 1999 by the merger between Astra and Zeneca, this Big Pharma company is 
based in the United Kingdom (with the second most important office present in Sweden). This 
company presents a low level of externally sourced sales (considering the company activity 
only after the mega-merger) and a significantly high diversification level. It employs around 
57,000 collaborators and presented sales level of around 34 billion USD in 2011. AstraZeneca 
does not sell generic or biosimilar products and is focused in several therapy areas; the most 
relevant in sales terms are: cardiovascular, gastroenterology, central nervous system diseases, 
oncology and respiratory. 
Baxter  
Baxter is a US-based Mid Pharma company employing around 48,500 collaborators and 
presenting a 2011 sales level of around 14 billion USD, from which around 3% are generics 
or biosimilar products, area in which the company invested in the beginning of the XXI 
century (and has been decreasing in total sales in the period 2007-2011). This “medium-to-
highly” diversified firm was founded in 1931 and presents an average level of externally 
sourced sales (M&A, strategic partnerships and outsourcing). The two most important therapy 
areas in sales’ terms for Baxter are hematology and, immunology and inflammation. 
Bayer  
This German Big Pharma highly-diversified company is one of the oldest big players in the 
pharmaceutical scene, since it was founded in 1863 and employs around 112,000 
collaborators throughout the world, presenting around 51 billion USD sales level in 2011. 
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This company is highly investing in externally sourced sales, with most of this activity taking 
place in the form of M&A (mainly acquisitions). Also, Bayer has been increasingly investing 
in the generics market, and sales have grown from around 50 million USD in 2007 to 73 
million USD in 2011. Bayer plays in a great number of therapy areas, with the most important 
being the Genitourinary, but also having an important position in cardiovascular, central 
nervous system diseases, hematology, oncology and infectious disease. 
Biogen Idec 
This research-based US-based biopharmaceutical Mid Pharma company which was founded 
in 2003, is one of the least diversified companies in the sample. It focuses its research and, 
consequently, its sales in oncology and central nervous system diseases. Biogen Idec employs 
around 5,000 collaborators worldwide, presenting around 5 billion USD sales level in 2011. 
Although Biogen Idec presents some externally sourced sales (mainly through acquisitions), 
most of its sales are internally generated. Also, Biogen Idec does not present generic or 
biosimilar products’ sales. 
 Bristol-Myers Squibb 
This global pharmaceutical company is based in the US and was founded in 1887, employing 
around 28,000 employees worldwide and presented sales volume of around 21 billion USD in 
2011. It presents a great diversification level, presenting as major therapy areas: 
cardiovascular, infectious disease, central nervous system disease and oncology. Moreover, 
Bristol-Myers Squibb presents a relevant level of externally sourced sales, mostly through 
strategic partnerships and co-developed products, methods in which the company is highly 
investing since the beginning of the XXI century. 
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Celgene Corporation 
This US-based Mid Pharma company was founded in 1986 and employs around 4,500 
collaborators throughout the world which generated around 4.9 billion USD sales level in 
2011. It presents a very low diversification level, concentrating almost all its sales in the 
oncology therapy area. It presents no generic or biosimilar products’ sales and a very low 
level of externally sourced products.    
Eli Lilly and Company 
This highly innovative US-based Big Pharma company was founded in 1876 and holds long-
time expertise in specific therapy areas where it is major player: central nervous system, 
endocrine, metabolic & genetic disorders (being an important player in diabetes care), 
genitourinary and oncology. Although Eli Lilly does not present a highly diversified portfolio 
when compared to other companies in the sample, it presents high market shares in most of 
the aforementioned therapy areas. Besides, this firm presents a low level of M&A activity and 
strategic partnerships occurrence. It employs around 38,500 collaborators worldwide and 
generated a sales level around 25 billion USD in 2011. 
Forest Laboratories 
This US-based Mid Pharma company was founded in 1954 and employs around 5,500 
collaborators worldwide generating around 4.5 billion USD of sales in 2011. This company’s 
portfolio is limited, with most of its sales occurring in the central nervous system diseases 
sector, where it holds great expertise. However, the company has been investing in selling 
generic and biosimilar products which accounted for 28 million USD in 2011 (less than 1% of 
total worldwide sales). At last, the company has not been investing heavily in strategic 
partnerships or co-development of products, since Forest focuses in the production of 
solutions for patients with central nervous system diseases.  
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Gilead Sciences 
This US-based Mid Pharma company was founded in 1987 and employs around 4,000 
collaborators worldwide generating around 8 billion USD of sales in 2011. This company’s 
portfolio is mainly focused in products associated with the prevention and treatment of 
infectious disease, therapy area which accounts for more than 90% of Gilead’s worldwide 
prescription sales. Although a great part of the sales are internally generated, there is a 
relevant portion of sales which is generated through co-development agreements which the 
company holds with other pharmaceutical companies. Gilead has not engaged in selling 
generic and biosimilar products. 
Glaxo SmithKline 
As the result of the mega-merger between Glaxo Wellcome and SmithKline Beecham, this 
UK-based company was founded in 2000, employing almost 100,000 collaborators 
throughout all its worldwide offices and research or manufacturing facilities. It presents a 
highly diversified portfolio, with the most important therapy areas being: infectious diseases, 
respiratory, central nervous system diseases and cardiovascular. 
 Johnson & Johnson 
This US-based highly diversified company was founded in 1886 and employs around 118,000 
collaborators worldwide (the second biggest record in the sample studied in this research). 
Although highly diversified in terms of therapy areas, Johnson & Johnson’s prescription sales 
are majorly focused in central nervous system diseases and immunology and inflammation 
(area in which the company has been investing in the last years, almost doubling this area’s 
sales volume between 2007 and 2011). Johnson & Johnson has also invested recently in 
generics production, although its generic products’ sales account for around 1% of the total 
prescription sales in 2011. At last, Johnson & Johnson presents a medium-to-high external 
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growth source ratio, since it has been investing majorly in M&A activity and in-licensed 
products. Its total sales volume was around 65 billion USD in 2011. 
Lundbeck 
This Mid Pharma Danish company was founded in 1915 and employs almost 3,000 
collaborators worldwide and presents assets which are worth around 3.8 billion USD – it is 
one of the smallest companies within the studied sample. It presents a really low EGS ratio, 
since it internally developed products which accounted for around 70% of total prescription 
sales in 2011. This company is highly specialized in central nervous system diseases, although 
it has been investing in lightly diversifying its portfolio in the last years (in 2007, central 
nervous system diseases accounted for 100% of the prescription sales while, in 2011, it 
accounted for 98%, with the next higher therapy area being cardiovascular).  
Merck & Co. (Merck, Sharp & Dohme outside the US and Canada) 
This US-based highly diversified Big Pharma company was founded in 1891 as the American 
subsidiary of Merck KGaA and became independent from that company in 1917. Nowadays 
it employs around 86,000 collaborators worldwide. It presents an average EGS ratio level, 
presenting some M&A activity and co-development agreements. In what concerns the most 
important therapy areas, there are five areas in which the company achieved over 4 billion 
USD sales in 2011: infectious diseases, respiratory, cardiovascular, endocrine, metabolic & 
genetic disorders and, immunology and inflammation. The company does not present generic 
or biosimilar products’ sales. 
Merck KGaA 
This Germany-based Mid Pharma company is one of the oldest pharmaceutical companies 
worldwide – it was founded in 1668. It currently employs around 41,000 collaborators 
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worldwide and presented around 14 billion USD sales level in 2011. It presents a significant 
level of “sales externalization”, with M&A, in-licensed and acquired products accounting for 
around 60% of 2011 sales volume. It does not present generic and biosimilar products’ sales 
but presents a highly diversified portfolio - the most important therapy areas are: central 
nervous system diseases, genitourinary, oncology and cardiovascular. 
Novartis 
Novartis is a Swiss Big Pharma company employing around 120,000 collaborators worldwide 
(biggest number of employees from this research sample) which contributed for a sales level 
of around 60 billion USD in 2011. This company is the most diversified company in terms of 
pharmaceutical therapy area (from this research sample) – the most important areas are 
cardiovascular, oncology, central nervous system diseases, infectious diseases and, 
immunology and inflammation. Novartis presents a low level of co-operation with other 
pharmaceutical firms, and generic and biosimilar products’ sales account for around 16% of 
the total prescription sales in 2011 (around 9 billion USD in generic and biosimilar products’ 
sales in 2011).    
Novo Nordisk 
Novo Nordisk is a Danish Big Pharma company which was founded in 1923. It employs 
around 31,000 collaborators worldwide and presents a highly-concentrated portfolio (in 
endocrine, metabolic and genetic disorders being the most important therapy area – since 
Novo Nordisk is the world leader in diabetes care). It presented a sales level of around 12 
billion USD in 2011, all of them being generated through internally developed products (there 
is no M&A activity and no co-development agreements). 
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Pfizer 
This is a US-based Big Pharma company which was founded in 1849 and presents the highest 
asset value from the whole research sample: 188 billion USD. It employs around 104,000 
collaborators worldwide and generated a 2011 sales level of around 67.5 billion USD. It is, 
without a doubt, one of the most important players in the pharmaceutical scene, presenting a 
high level of portfolio diversification (in what concerns therapy areas), presenting five therapy 
areas where sales level were higher than 5 billion USD in 2011: cardiovascular, central 
nervous system diseases, infectious diseases, immunology and inflammation, and 
genitourinary. It is one of the firms presenting higher EGS level, with sales of products 
acquired through M&A activity accounting for around 67% of total prescription sales of 2011. 
Roche 
This multinational pharmaceutical firm was founded in Switzerland in 1896 and employs 
around 81,000 collaborators worldwide nowadays. It presents an average level of portfolio 
diversification, with the most important therapy areas being: oncology (accounting for more 
than 55% of total prescription sales), infectious diseases and, immunology and inflammation. 
It presents a high level of externally sourced sales, mainly through M&A activity – products 
acquired through M&A activity accounted for around 68% of total prescription sales in 2011. 
The company does not sell any generic or biosimilar products and presented sales level of 
around 48 billion USD in 2011. 
Sanofi-Aventis 
This French multinational pharmaceutical company was founded in 2004 in France by the 
merger of Aventis and Sanofi-Synthélabo. It presents a highly diversified portfolio, with five 
of its therapy areas presenting sales level above 4 billion USD in 2011: cardiovascular, 
endocrine, metabolic & genetic disorders, infectious diseases, oncology and central nervous 
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system diseases. These contributed to an overall prescription sales level of 48 billion USD in 
2011, generated through its 114,000 employees’ effort. Around 5% of 2011 prescription sales 
were represented by generic and biosimilar products (around 2.5 billion USD). At last, Sanofi-
Aventis is engaging in M&A activity and in a great number of co-development agreements 
(which generate together around 68% of the whole prescription sales). 
Shire 
This specialty biopharmaceutical Irish company was founded in 1986 and employs around 
5,400 collaborators worldwide. This Mid Pharma company invests a lot in externally sourced 
products (presenting the highest EGS ratio of the whole research sample), mainly through 
M&A activity. It presents a medium-to-low diversification level, since it heavily relies in its 
central nervous system diseases and endocrine, metabolic & genetic disorders units (which 
account for around 73% of the total prescription sales) although it holds business in several 
other therapy areas presenting lower level of importance. 
UCB 
This Belgium-based Mid Pharma company which was founded in 1928, employs around 
9,000 collaborators worldwide and presents a medium-to-low portfolio diversification level, 
since its business heavily relies on its central nervous system disease unit (55%) – also 
holding business in other areas, although they do not present relevance in sales terms. It 
presented total prescription sales of around 4.5 billion USD, from which 4% were related to 
generic or biosimilar products’ sales. The company invests either in internally developed 
products (55% of total prescription sales in 2011) or in products acquired through M&A 
activity (37% of total prescription sales in 2011).  
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Warner-Chilcott  
This Irish Mid Pharma company was founded in 1968 and employs around 2,700 
collaborators worldwide. Its 2011 sales level were around 2.7 billion USD, for which highly 
contributed its genitourinary and musculoskeletal therapy areas accounting for 33% and 30% 
of total prescription sales worldwide respectively. It presents a high level of externally sourced 
products (64% of total prescription sales). This company does not present any sales of generic 
or biosimilar products.   
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Appendix 9.9: 
Sample general characterization 
 
All data was drawn from the companies’ fundamentals for the period 2007-2011, 
namely the balance sheet and the income statement. The sample comprises twenty six firms 
from different countries: US (thirteen), Switzerland (three), the UK (two), Ireland (two), 
Denmark (two), Germany (two), France (one) and Belgium (one). The research covers the 
period between 2007 and 2011. This is because 2011 is the most recent year for which 
information is available, and 2007 because, considering the fast-pace at which the 
pharmaceutical industry is changing and the fact that its cycles are short, differences between 
2000 and 2010 might be great, biasing this research – which aims to demonstrate and prove 
identified trends in the pharmaceutical industry in the last years. 
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The average number of employees of the sample firms is 47,644. However, as 
observed in graph 9.9.2 most firms have either more than 80,000 or less than 20,000 
employees – the mix of firms is comprised by both big and small firms. Number of 
employees can be used as a proxy measure of firm size, although sales’ level is also a relevant 
figure to determine it (and the one used throughout the research). As it is observed in graph 
9.9.3 most firms perform sales’ levels below 50 billion USD. Besides, there is a balanced 
distribution of low, medium and high product diversified companies as it is observed in graph 
9.9.4. This is important in order to avoid bias in the conclusions about the correlation between 
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diversification level and performance. Most companies acting in this industry already have a 
long number of years of expertise and market experience. As it can be seen in the graph 9.9.5, 
a great part of the companies was formed earlier than 18 years from now, having large 
experience in the industry. It is worth mention that some companies identified as belonging to 
the post-1985 segment, resulted of M&A processes, thus, having more time in the market than 
it seems by the presented firm breakdown. 
Brief characterization of the sample firms: 
Company 
 
Country 
 
Founded in Nr. Employees 2011 
Sales 2011 
(m USD) 
CR 2011 
Abbott United States 1888 91,000 38,851 0.20 
Actelion Switzerland 1997 2,500 2,026 0.92 
Allergan United States 1948 8,500 5,419 0.50 
Amgen United States 1980 17,800 15,582 0.34 
AstraZeneca United Kingdom 1999 57,200 33,591 0.21 
Baxter United States 1931 48,500 13,893 0.30 
Bayer Germany 1863 111,800 50,821 0.17 
Biogen Idec United States 2003 5,000 5,049 0.62 
Bristol-Myers Squibb United States 1887 28,000 21,244 0.26 
Celgene United States 1986 4,300 4,842 0.99 
Eli Lilly United States 1876 38,350 24,286 0.29 
Forest United States 1954 5,700 4,586 0.73 
Gilead United States 1987 4,000 8,385 0.86 
GlaxoSmith Kline United Kingdom 2000 98,000 43,922 0.25 
Johnson & Johnson United States 1886 118,000 65,030 0.24 
Lundbeck Denmark 1915 6,000 2,989 0.97 
Merck & Co. United States 1917 86,000 48,047 0.15 
Merck KGaA Germany 1668 41,000 14,297 0.19 
Novartis Switzerland 1996 120,000 59,365 0.14 
Novo Nordisk Denmark 1923 31,000 12,389 0.70 
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Company 
 
Country 
 
Founded in Nr. Employees 2011 
Sales 2011 
(m USD) 
CR 2011 
Pfizer United States 1849 104,000 67,425 0.15 
Roche Switzerland 1896 81,000 47,974 0.36 
Sanofi France 2004 114,000 48,776 0.15 
Shire Ireland 1986 5,400 4,263 0.31 
UCB Belgium 1928 9,000 4,516 0.36 
Warner-Chilcott Ireland 1968 2,700 2,728 0.29 
 
“CR 2011” in the table stands for Concentration ratio level in 2011 for each of the firms. 
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Appendix 9.10: 
Database short version – variables used in the Research Questions 
Sample for the year 2007 
Company Country Year ROA 1/DOL GSM AT 
R&D/ 
REV 
CR EGS 
Abbott United States 2007 0.12 0.34 0.56 0.65 10% 18% 51% 
Actelion Switzerland 2007 0.09 0.13 0.90 0.79 22% 95% 6% 
Allergan United States 2007 0.11 0.21 0.83 0.60 16% 48% 55% 
Amgen United States 2007 0.12 0.35 0.83 0.43 22% 37% 24% 
AstraZeneca United Kingdom 2007 0.17 0.35 0.78 0.62 17% 19% 4% 
Baxter United States 2007 0.14 0.39 0.49 0.74 7% 27% 20% 
Bayer Germany 2007 0.10 0.33 0.50 0.63 8% 17% 59% 
Biogen Idec United States 2007 0.11 0.34 0.89 0.37 29% 56% 32% 
Bristol-Myers Squibb United States 2007 0.15 0.30 0.68 0.74 17% 31% 34% 
Celgene United States 2007 0.15 0.41 0.91 0.39 28% 99% 0% 
Eli Lilly United States 2007 0.15 0.27 0.77 0.70 19% 30% 7% 
Forest United States 2007 0.24 0.38 0.79 0.82 18% 83% 2% 
Gilead United States 2007 0.37 0.63 0.82 0.72 14% 99% 31% 
GlaxoSmithKline United Kingdom 2007 0.25 0.44 0.77 0.73 15% 22% 8% 
Johnson & Johnson United States 2007 0.16 0.30 0.71 0.75 13% 28% 25% 
Lundbeck Denmark 2007 0.21 0.29 0.80 0.89 20% 100% 2% 
Merck & Co. United States 2007 0.08 0.21 0.75 0.50 20% 19% 23% 
Merck KGaA Germany 2007 0.32 0.90 0.75 0.47 15% 19% 51% 
Novartis Switzerland 2007 0.17 0.45 0.72 0.52 17% 17% 9% 
Novo Nordisk Denmark 2007 0.23 0.34 0.77 0.88 20% 69% 0% 
Pfizer United States 2007 0.07 0.22 0.77 0.42 17% 22% 59% 
Roche Switzerland 2007 0.20 0.47 0.70 0.59 18% 27% 58% 
Sanofi France 2007 0.09 0.30 0.74 0.41 16% 17% 66% 
Shire Ireland 2007 -0.32 -0.65 0.87 0.56 23% 35% 77% 
UCB Belgium 2007 0.04 0.13 0.71 0.38 22% 30% 23% 
Warner-Chilcott Ireland 2007 0.06 0.23 0.79 0.31 6% 37% 58% 
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Database short version – variables used in the Research Questions 
Sample for the year 2008 
Company Country Year ROA 1/DOL GSM AT 
R&D/ 
REV 
CR EGS 
Abbott United States 2008 0.15 0.38 0.57 0.70 9% 18% 57% 
Actelion Switzerland 2008 0.18 0.28 0.89 0.72 25% 95% 7% 
Allergan United States 2008 0.12 0.22 0.83 0.65 18% 47% 56% 
Amgen United States 2008 0.15 0.44 0.85 0.41 20% 35% 26% 
AstraZeneca United Kingdom 2008 0.20 0.37 0.79 0.68 16% 18% 6% 
Baxter United States 2008 0.16 0.41 0.50 0.80 7% 28% 19% 
Bayer Germany 2008 0.04 0.14 0.50 0.63 8% 18% 61% 
Biogen Idec United States 2008 0.14 0.31 0.90 0.48 26% 57% 30% 
Bristol-Myers Squibb United States 2008 0.26 0.55 0.69 0.70 17% 30% 35% 
Celgene United States 2008 -0.31 -0.68 0.89 0.51 41% 98% 11% 
Eli Lilly United States 2008 -0.04 -0.08 0.79 0.70 19% 29% 8% 
Forest United States 2008 0.19 0.31 0.79 0.75 17% 83% 1% 
Gilead United States 2008 0.38 0.64 0.79 0.76 14% 96% 37% 
GlaxoSmithKline United Kingdom 2008 0.18 0.40 0.74 0.62 15% 24% 8% 
Johnson & Johnson United States 2008 0.20 0.38 0.71 0.75 12% 27% 29% 
Lundbeck Denmark 2008 0.18 0.24 0.84 0.90 27% 100% 2% 
Merck & Co. United States 2008 0.21 0.55 0.77 0.51 20% 19% 17% 
Merck KGaA Germany 2008 0.05 0.13 0.75 0.48 16% 18% 50% 
Novartis Switzerland 2008 0.12 0.30 0.73 0.54 17% 17% 9% 
Novo Nordisk Denmark 2008 0.24 0.35 0.78 0.90 17% 70% 0% 
Pfizer United States 2008 0.08 0.22 0.83 0.43 16% 21% 61% 
Roche Switzerland 2008 0.18 0.44 0.70 0.60 19% 31% 64% 
Sanofi France 2008 0.07 0.24 0.75 0.40 16% 17% 70% 
Shire Ireland 2008 0.09 0.14 0.86 0.77 17% 36% 76% 
UCB Belgium 2008 0.02 0.07 0.68 0.38 21% 37% 20% 
Warner-Chilcott Ireland 2008 0.04 0.15 0.79 0.36 5% 37% 53% 
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Database short version – variables used in the Research Questions 
Sample for the year 2009 
Company Country Year ROA 1/DOL GSM AT 
R&D/ 
REV 
CR EGS 
Abbott United States 2009 0.14 0.43 0.57 0.59 9% 20% 64% 
Actelion Switzerland 2009 0.13 0.23 0.90 0.67 26% 94% 8% 
Allergan United States 2009 0.12 0.24 0.83 0.60 16% 49% 55% 
Amgen United States 2009 0.15 0.46 0.86 0.37 20% 33% 26% 
AstraZeneca United Kingdom 2009 0.25 0.50 0.82 0.60 13% 19% 7% 
Baxter United States 2009 0.16 0.43 0.52 0.72 7% 29% 15% 
Bayer Germany 2009 0.04 0.12 0.51 0.61 9% 18% 59% 
Biogen Idec United States 2009 0.16 0.33 0.91 0.51 29% 59% 27% 
Bristol-Myers Squibb United States 2009 0.42 0.96 0.73 0.61 19% 29% 36% 
Celgene United States 2009 0.17 0.36 0.92 0.50 30% 99% 16% 
Eli Lilly United States 2009 0.20 0.32 0.81 0.80 20% 29% 9% 
Forest United States 2009 0.15 0.29 0.78 0.67 25% 81% 1% 
Gilead United States 2009 0.36 0.65 0.77 0.72 13% 91% 43% 
GlaxoSmithKline United Kingdom 2009 0.20 0.41 0.74 0.66 14% 26% 8% 
Johnson & Johnson United States 2009 0.17 0.37 0.70 0.65 11% 24% 36% 
Lundbeck Denmark 2009 0.16 0.24 0.81 0.80 23% 91% 8% 
Merck & Co. United States 2009 0.14 0.84 0.67 0.24 21% 18% 22% 
Merck KGaA Germany 2009 0.04 0.11 0.74 0.46 17% 19% 49% 
Novartis Switzerland 2009 0.11 0.31 0.73 0.47 17% 16% 11% 
Novo Nordisk Denmark 2009 0.25 0.34 0.80 0.93 15% 69% 0% 
Pfizer United States 2009 0.05 0.25 0.82 0.23 16% 19% 62% 
Roche Switzerland 2009 0.17 0.36 0.70 0.66 20% 31% 61% 
Sanofi France 2009 0.09 0.31 0.74 0.38 15% 17% 71% 
Shire Ireland 2009 0.14 0.25 0.87 0.65 21% 32% 71% 
UCB Belgium 2009 0.09 0.40 0.67 0.34 22% 35% 26% 
Warner-Chilcott Ireland 2009 0.11 0.57 0.83 0.24 5% 24% 65% 
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Database short version – variables used in the Research Questions 
Sample for the year 2010 
Company Country Year ROA 1/DOL GSM AT 
R&D/ 
REV 
CR EGS 
Abbott United States 2010 0.10 0.30 0.58 0.59 11% 19% 75% 
Actelion Switzerland 2010 0.16 0.27 0.90 0.66 25% 93% 7% 
Allergan United States 2010 0.03 0.06 0.85 0.59 16% 48% 58% 
Amgen United States 2010 0.13 0.43 0.85 0.35 19% 33% 26% 
AstraZeneca United Kingdom 2010 0.25 0.53 0.81 0.59 16% 20% 5% 
Baxter United States 2010 0.11 0.33 0.46 0.73 7% 29% 15% 
Bayer Germany 2010 0.03 0.10 0.51 0.68 9% 18% 57% 
Biogen Idec United States 2010 0.15 0.28 0.92 0.58 26% 61% 25% 
Bristol-Myers Squibb United States 2010 0.20 0.43 0.73 0.63 18% 29% 37% 
Celgene United States 2010 0.10 0.22 0.90 0.48 28% 99% 18% 
Eli Lilly United States 2010 0.21 0.35 0.81 0.74 21% 29% 10% 
Forest United States 2010 0.19 0.39 0.78 0.64 16% 79% 1% 
Gilead United States 2010 0.34 0.65 0.76 0.69 13% 88% 48% 
GlaxoSmithKline United Kingdom 2010 0.09 0.19 0.73 0.68 16% 25% 8% 
Johnson & Johnson United States 2010 0.17 0.39 0.69 0.63 12% 22% 41% 
Lundbeck Denmark 2010 0.18 0.25 0.81 0.89 18% 91% 14% 
Merck & Co. United States 2010 0.02 0.25 0.33 0.26 41% 15% 47% 
Merck KGaA Germany 2010 0.05 0.16 0.74 0.41 15% 19% 48% 
Novartis Switzerland 2010 0.10 0.33 0.72 0.42 18% 15% 11% 
Novo Nordisk Denmark 2010 0.33 0.41 0.81 0.99 16% 69% 0% 
Pfizer United States 2010 0.05 0.18 0.76 0.35 14% 15% 67% 
Roche Switzerland 2010 0.22 0.39 0.72 0.78 21% 34% 67% 
Sanofi France 2010 0.08 0.30 0.73 0.38 14% 16% 69% 
Shire Ireland 2010 0.15 0.27 0.87 0.64 19% 30% 69% 
UCB Belgium 2010 0.02 0.09 0.67 0.36 22% 37% 31% 
Warner-Chilcott Ireland 2010 0.10 0.23 0.87 0.53 5% 26% 84% 
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Database short version – variables used in the Research Questions 
Sample for the year 2011 
Company Country Year ROA 1/DOL GSM AT 
R&D/ 
REV 
CR EGS 
Abbott United States 2011 0.09 0.24 0.60 0.64 11% 20% 77% 
Actelion Switzerland 2011 -0.03 -0.05 0.89 0.66 25% 92% 7% 
Allergan United States 2011 0.16 0.29 0.86 0.64 17% 50% 59% 
Amgen United States 2011 0.09 0.34 0.84 0.32 20% 34% 30% 
AstraZeneca United Kingdom 2011 0.29 0.56 0.82 0.64 16% 21% 6% 
Baxter United States 2011 0.15 0.41 0.51 0.73 7% 30% 14% 
Bayer Germany 2011 0.06 0.18 0.51 0.69 8% 17% 54% 
Biogen Idec United States 2011 0.19 0.37 0.91 0.56 24% 62% 23% 
Bristol-Myers Squibb United States 2011 0.21 0.45 0.74 0.64 18% 26% 39% 
Celgene United States 2011 0.14 0.33 0.90 0.48 28% 99% 24% 
Eli Lilly United States 2011 0.19 0.33 0.79 0.72 21% 29% 11% 
Forest United States 2011 0.17 0.35 0.78 0.61 17% 73% 2% 
Gilead United States 2011 0.22 0.60 0.75 0.48 14% 86% 49% 
GlaxoSmithKline United Kingdom 2011 0.20 0.43 0.72 0.67 15% 25% 10% 
Johnson & Johnson United States 2011 0.11 0.29 0.69 0.57 12% 24% 47% 
Lundbeck Denmark 2011 0.16 0.26 0.81 0.78 18% 97% 15% 
Merck & Co. United States 2011 0.07 0.25 0.65 0.46 18% 15% 45% 
Merck KGaA Germany 2011 0.05 0.15 0.73 0.46 15% 19% 48% 
Novartis Switzerland 2011 0.09 0.27 0.68 0.51 16% 14% 10% 
Novo Nordisk Denmark 2011 0.35 0.42 0.81 1.03 15% 70% 0% 
Pfizer United States 2011 0.07 0.24 0.78 0.36 14% 15% 68% 
Roche Switzerland 2011 0.22 0.44 0.72 0.69 20% 36% 69% 
Sanofi France 2011 0.05 0.22 0.69 0.35 14% 15% 69% 
Shire Ireland 2011 0.17 0.30 0.86 0.67 18% 31% 72% 
UCB Belgium 2011 0.04 0.15 0.69 0.35 24% 36% 37% 
Warner-Chilcott Ireland 2011 0.13 0.27 0.88 0.54 4% 29% 86% 
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Appendix 9.11: 
Gross sales margin by region average (2007-2011) 
 
 
Sample limits: [0.73;0.76]; US firms’ limits: [0.75;0.76]; European firms’ limits: [0.73;0.76] 
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Appendix 9.12: 
Inverse of the degree of operating leverage by region average (2007-2011) 
 
Sample limits: [0.25;0.45]; US firms’ limits: [0.28;0.45]; European firms’ limits: [0.25;0.32] 
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Appendix 9.13: 
Asset Turnover by region average (2007-2011) 
 
 
 
Sample limits: [0.56;0.63]; US firms’ limits: [0.56;0.63]; European firms’ limits: [058;0.62] 
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Appendix 9.14: 
9.14.1. Correlation coefficients model for the sample of Branded Pharmaceuticals (1): 
9.14.2. Correlation coefficients model for the sample of Branded Pharmaceuticals (2): 
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9.14.3. Part of the output from SPSS regarding correlations between different variables 
Part of the correlations matrix obtained through SPSS 
  ROA ROE 1/DOL GSM AT R&D/REV CR EGS 
Country Pearson Correlation -.158 -.103 -.175* -.001 -.127 -.233** -.089 .171 
Sig. (2-tailed) .073 .244 .047 .989 .151 .008 .314 .051 
N 130 130 130 130 130 130 130 130 
Region Pearson Correlation -.091 -.009 -.171 .023 .075 -.107 -.107 .039 
Sig. (2-tailed) .306 .917 .051 .794 .397 .226 .227 .659 
N 130 130 130 130 130 130 130 130 
ROA Pearson Correlation 1 .483** .869** .085 .465** -.173* .219* -.286** 
Sig. (2-tailed)   .000 .000 .335 .000 .049 .012 .001 
N 130 130 130 130 130 130 130 130 
ROE Pearson Correlation .483** 1 .447** -.051 .206* -.097 .017 -.109 
Sig. (2-tailed) .000   .000 .565 .019 .273 .845 .216 
N 130 130 130 130 130 130 130 130 
1/DOL Pearson Correlation .869** .447** 1 -.095 .076 -.244** -.042 -.125 
Sig. (2-tailed) .000 .000   .283 .393 .005 .638 .157 
N 130 130 130 130 130 130 130 130 
GSM Pearson Correlation .085 -.051 -.095 1 -.022 .439** .511** -.180* 
Sig. (2-tailed) .335 .565 .283   .808 .000 .000 .041 
N 130 130 130 130 130 130 130 130 
AT Pearson Correlation .465** .206* .076 -.022 1 -.135 .377** -.373** 
Sig. (2-tailed) .000 .019 .393 .808   .127 .000 .000 
N 130 130 130 130 130 130 130 130 
R&D/REV Pearson Correlation -.173* -.097 -.244** .439** -.135 1 .446** -.339** 
Sig. (2-tailed) .049 .273 .005 .000 .127   .000 .000 
N 130 130 130 130 130 130 130 130 
CR Pearson Correlation .219* .017 -.042 .511** .377** .446** 1 -.430** 
Sig. (2-tailed) .012 .845 .638 .000 .000 .000   .000 
N 130 130 130 130 130 130 130 130 
EGS Pearson Correlation -.286** -.109 -.125 -.180* -.373** -.339** -.430** 1 
Sig. (2-tailed) .001 .216 .157 .041 .000 .000 .000   
N 130 130 130 130 130 130 130 130 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Appendix 9.15: 
Cluster analysis – SPSS outputs: 
9.15.1 Cluster Membership 
 
Cluster Membership 
Case Number Name Cluster Distance 
1 Abbott 5 8566,893 
2 Actelion 2 5161,046 
3 Allergan 2 333,151 
4 Amgen 1 9131,137 
5 AstraZeneca 5 7700,996 
6 Baxter 2 9045,131 
7 Bayer 5 12700,469 
8 Biogen Idec 2 683,406 
9 Bristol-Myers Squibb 1 1328,192 
10 Celgene 2 1152,199 
11 Eli Lilly 1 1859,895 
12 Forest 2 1805,928 
13 Gilead 2 2411,229 
14 GlaxoSmithKline 5 3567,797 
15 Johnson & Johnson 4 1351,471 
16 Lundbeck 2 4868,129 
17 Merck & Co. 4 10360,625 
18 Merck KGaA 1 5945,621 
19 Novartis 4 3944,800 
20 Novo Nordisk 2 2548,359 
21 Pfizer 3 ,000 
22 Roche 4 14777,665 
23 Sanofi 4 19843,504 
24 Shire 2 2948,027 
25 UCB 2 5018,189 
26 Warner-Chilcott 2 3436,925 
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9.15.2 Final Cluster Centers 
 
Final Cluster Centers 
 Cluster 
1 2 3 4 5 
Number of years since 
foundation 
158,25 50,50 162,00 71,20 73,50 
EBIT/Assets ,16 ,15 ,06 ,13 ,15 
TOTAL_ASSETS 31483,75 7877,92 164476,00 94069,60 59424,75 
R&D/Revenue ,19 ,19 ,15 ,18 ,12 
Concentration Ratio ,28 ,64 ,18 ,21 ,20 
External Growth Source 
Ratio 
,30 ,28 ,63 ,42 ,34 
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Appendix 9.16: 
Cluster analysis – Cluster presentation: 
 
 
 
 
 
 
 
